<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article article-type="review-article" dtd-version="1.1" specific-use="sps-1.9" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
	<front>
		<journal-meta>
			<journal-id journal-id-type="nlm-ta">Rev Saude Publica</journal-id>
			<journal-id journal-id-type="publisher-id">rsp</journal-id>
			<journal-title-group>
				<journal-title>Revista de Saúde Pública</journal-title>
				<abbrev-journal-title abbrev-type="publisher">Rev. Saúde Pública</abbrev-journal-title>
			</journal-title-group>
			<issn pub-type="ppub">0034-8910</issn>
			<issn pub-type="epub">1518-8787</issn>
			<publisher>
				<publisher-name>Faculdade de Saúde Pública da Universidade de São Paulo</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="other">00501</article-id>
			<article-id pub-id-type="doi">10.11606/s1518-8787.2022056004311</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Review</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Systemic arterial hypertension as a risk factor for the severe form of covid-19: scoping review</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-0493-8376</contrib-id>
					<name>
						<surname>Ribeiro</surname>
						<given-names>Ana Cristina</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>I</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-0236-5025</contrib-id>
					<name>
						<surname>Uehara</surname>
						<given-names>Sílvia Carla da Silva André</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>I</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1">
				<label>I</label>
				<institution content-type="orgname">Universidade Federal de São Carlos</institution>
				<institution content-type="orgdiv1">Departamento de Enfermagem</institution>
				<addr-line>
					<named-content content-type="city">São Carlos</named-content>
					<named-content content-type="state">SP</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original">Universidade Federal de São Carlos. Departamento de Enfermagem. São Carlos, SP, Brasil</institution>
			</aff>
			<author-notes>
				<corresp id="c01"> Correspondence: Sílvia Carla da Silva André Uehara Rodovia Washington Luís, s/n, km 235 13565-905 São Carlos, SP, Brasil E-mail: <email>silviacarla@ufscar.br</email>
				</corresp>
				<fn fn-type="con">
					<p><bold>Authors’ Contribution:</bold> Study conception and planning: ACR, SCSAU. Data collection, analysis and interpretation: ACR, SCSAU. Manuscript elaboration or review: ACR, SCSAU. Final version approval: ACR, SCSAU. Public responsibility for the article’s content: ACR, SCSAU.</p>
				</fn>
				<fn fn-type="conflict">
					<p><bold>Conflict of Interest:</bold> The authors declare there is no conflict of interest.</p>
				</fn>
			</author-notes>
			<pub-date date-type="pub" publication-format="electronic">
				<day>08</day>
				<month>04</month>
				<year>2022</year>
			</pub-date>
			<pub-date date-type="collection" publication-format="electronic">
				<year>2022</year>
			</pub-date>
			<volume>56</volume>
			<elocation-id>20</elocation-id>
			<history>
				<date date-type="received">
					<day>17</day>
					<month>10</month>
					<year>2021</year>
				</date>
				<date date-type="accepted">
					<day>10</day>
					<month>01</month>
					<year>2022</year>
				</date>
			</history>
			<permissions>
				<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
					<license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p>
				</license>
			</permissions>
			<abstract>
				<title>ABSTRACT</title>
				<sec>
					<title>OBJECTIVE</title>
					<p> Identify whether systemic arterial hypertension is a risk factor for the severe form of covid-19.</p>
				</sec>
				<sec>
					<title>METHODS</title>
					<p> This is a scoping review, searches were performed on the Lilacs, PubMed, SciELO and Web of Science databases.</p>
				</sec>
				<sec>
					<title>RESULTS</title>
					<p> Thirteen articles were selected. The studies presented systemic arterial hypertension as the most common chronic disease in subjects diagnosed with covid-19. Hypertensive subjects were older, and men were more likely to develop severe covid-19. Hypertensive subjects without antihypertensive treatment were associated with a higher risk of mortality.</p>
				</sec>
				<sec>
					<title>CONCLUSIONS</title>
					<p> subjects with chronic diseases tend to have a different clinical profile. Blood pressure should be controlled in hypertensive subjects that should be continuously monitored during the covid-19 infection.</p>
				</sec>
			</abstract>
			<kwd-group xml:lang="en">
				<kwd>COVID-19, complications</kwd>
				<kwd>Risk Factors</kwd>
				<kwd>Hypertension</kwd>
				<kwd>Review</kwd>
			</kwd-group>
			<funding-group>
				<award-group>
					<funding-source>Fapesp</funding-source>
					<award-id>2019/21219-7</award-id>
				</award-group>
				<award-group>
					<funding-source>CNPq</funding-source>
					<award-id>402507/2020-7</award-id>
				</award-group>
				<funding-statement>Funding: Fundação de Amparo à Pesquisa do Estado de São Paulo (Fapesp - Process 2019/21219-7). Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq - Process 402507/2020-7).</funding-statement>
			</funding-group>
			<counts>
				<fig-count count="2"/>
				<table-count count="4"/>
				<equation-count count="0"/>
				<ref-count count="44"/>
			</counts>
		</article-meta>
	</front>
	<body>
		<sec sec-type="intro">
			<title>INTRODUCTION</title>
			<p>Systemic arterial hypertension (SAH) affects more than 30% of the adult population, or more than one billion people, and is the leading cause of premature death worldwide<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref></sup>. The burden of disease disproportionately affects low- and middle-income countries, where two-thirds of cases are found. This is largely due to the increase of risk factors in these populations in recent decades. Approximately half of people living with hypertension is unaware of their condition, putting them at risk for preventable medical complications and death<sup><xref ref-type="bibr" rid="B2">2</xref></sup>.</p>
			<p>Hypertension is considered a chronic non-communicable disease (NCD). It is a multifactorial condition that depends on genetic and epigenetic, environmental and social factors. Its cut-off point is defined by systolic blood pressure (SBP) ≥ 140, and diastolic blood pressure (DBP) ≥ 90 mm Hg<sup><xref ref-type="bibr" rid="B3">3</xref></sup>. According to the Brazilian Guidelines on Hypertension - 2020, some of the main risk factors for developing SAH include genetics, aging, gender, ethnicity, overweight and/or obesity, high sodium intake, sedentary lifestyle, alcohol intake, as well as socioeconomic factors, including lower education, inadequate housing conditions, and low family income<sup><xref ref-type="bibr" rid="B3">3</xref></sup>.</p>
			<p>Recent studies point out that the existence of comorbidities, such as systemic arterial hypertension, in subjects with covid-19 could lead to unfavorable outcomes, including an increased risk of death<sup><xref ref-type="bibr" rid="B4">4</xref></sup>. In this scenario, studies have identified that hypertension is the most common chronic disease in subjects infected with the new coronaviruses, which may be justified by the high global prevalence<sup><xref ref-type="bibr" rid="B7">7</xref></sup>.</p>
			<p>Subjects with systemic arterial hypertension experience endothelial dysfunction, which appears as an imbalance between vasodilator and vasoconstrictor substances that directly affects vascular function. This is considered to be a major characteristic of the vascular bed in hypertensive subjects. Associated with the aging process, hypertension results in progressive stiffening and loss of compliance of the great arteries, and is crucial in the pathogenesis of cardiovascular complications related to the covid-19<sup><xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref></sup>.</p>
			<p>It is noteworthy that since SAH is often asymptomatic, subject may evolve to structural and/or functional changes in target organs such as heart, brain, kidneys, and vessels. This would increase susceptibility to the SARS-CoV-2, increasing the risk of unfavorable outcomes in people with covid-19<sup><xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B13">13</xref></sup>.</p>
			<p>Data on the impact of known and newly diagnosed hypertension in subjects with covid-19 are still very limited. One study, however, showed that insufficient control of blood pressure (BP) was independently associated with adverse outcomes in covid-19 and hypertensive subjects<sup><xref ref-type="bibr" rid="B14">14</xref></sup>.</p>
			<p>Another study reported that stage I hypertension was present in 37% of subjects hospitalized for covid-19, while the prevalence of stage II and III hypertension was significantly higher (61% and 70%, respectively). Unfavorable outcomes (mortality, septic shock, respiratory failure, acute respiratory distress syndrome [ARDS], and intensive care unit admission) gradually increased with elevated blood pressure<sup><xref ref-type="bibr" rid="B15">15</xref></sup>.</p>
			<p>It is also noteworthy that most hypertensive subjects require pharmacological treatment, especially with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), which has currently been analyzed whether or not their use may contribute to a higher risk of infection and/or severity of covid-19<sup><xref ref-type="bibr" rid="B16">16</xref></sup>.</p>
			<p>The covid-19 infection has a lethality of 2.2% worldwide, and currently more than four billion people have died in the world. In Brazil alone, by July 2021, more than 544,000 people died as a result of covid-19<sup><xref ref-type="bibr" rid="B17">17</xref></sup>. As for the relationship between hypertension and covid-19, hypertensive subjects with SARS-CoV-2 infection had 2.27 and 3.48 times higher risks of severity and fatality, respectively, compared to covid-19 cases without hypertension<sup><xref ref-type="bibr" rid="B18">18</xref></sup>.</p>
			<p>In this context, the relationship between hypertension and unfavorable outcomes of covid-19 are of great concern for public health, making it essential to conduct studies that clarify the relationship between the diagnosis of hypertension and the development of severe forms of covid-19. Thus, this article aims to identify whether SAH is a risk factor for the worsening of covid-19.</p>
		</sec>
		<sec sec-type="methods">
			<title>METHODS</title>
			<p>This is a scoping review, and followed the six methodological steps described by the Joanna Briggs Institute: (1) identification of the research question; (2) identification of relevant studies; (3) selection of studies; (4) data extraction; (5) sorting, summarizing, and reporting results; and (6) dissemination of results<sup><xref ref-type="bibr" rid="B19">19</xref></sup>.</p>
			<p>In order to construct the guiding question, we applied the PCC strategy, which represents a mnemonic for P (Population) (people diagnosed with SAH), C (Concept) (hospitalized people affected by covid-19), and C (Context) (covid-19 pandemic). The guiding question was defined as: Might people diagnosed with SAH have an increased risk for severe case of covid-19?</p>
			<p>Articles was searched on the Lilacs, PubMed, SciELO, and Web of Science databases from March to April 2021 by two researchers individually, and disagreements were discussed with a third researcher, and resolved by consensus. The search terms used were: hypertension, arterial hypertension, coronavirus, covid-19, Sars-coronavirus, and Sars-CoV-2 (<xref ref-type="table" rid="t1">Box 1</xref>).</p>
			<p>
				<table-wrap id="t1">
					<label>Box 1</label>
					<caption>
						<title>Search strategies used on the databases. São Carlos, SP, 2021.</title>
					</caption>
					<table frame="hsides" rules="groups">
						<colgroup>
							<col/>
							<col/>
						</colgroup>
						<thead>
							<tr>
								<th align="left">DATABASE</th>
								<th>SEARCH STRATEGIES</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td>PubMed</td>
								<td align="center">((hypertension[Title] OR “arterial hypertension”[Title]) AND (((coronavirus[Title] OR “COVID-19”[Title]) OR “SARS-CORONAVIRUS”[Title]) OR “SARS-COV-2”[Title])) NOT pulmonary[Title]</td>
							</tr>
							<tr>
								<td><italic>Web of Science</italic></td>
								<td align="center">TI=(hyperttension OR “arterial hypertension”) NOT TI=(pulmonary) AND TI=(coronavirus OR Covid-19 OR SARS-CORONAVIRUS OR SARS-COV-2)</td>
							</tr>
							<tr>
								<td>Lilacs</td>
								<td align="center">(hypertension OR arterial hypertension [Title words] and coronavirus OR Covid-19 OR sars-coronavirus OR Sars-cov-2 [Title words] and not pulmonary [Title words])</td>
							</tr>
							<tr>
								<td>SciELO</td>
								<td align="center">TI=(hypertension OR “arterial hypertension”) NOT TI=(pulmonary) AND TI=(coronavirus OR Covid-19 OR SARS-CORONAVIRUS OR SARS-COV-2)</td>
							</tr>
						</tbody>
					</table>
				</table-wrap>
			</p>
			<p>Searches were performed using descriptors and their synonyms found in the <italic>Descritor em Ciências da Saúde</italic> (DeCS) and Medical Subject Headings (MeSH) (<xref ref-type="table" rid="t1">Box 1</xref>).</p>
			<p>We included primary studies published in Portuguese, English, and Spanish between January and December 2020, and excluded articles whose titles and abstracts were not within the objective of the investigation, and studies that addressed other risk factors, as well as opinion articles, editorials, and reviews. The reference lists of all studies found were also checked.</p>
			<p>To select the studies, after implementing the search strategy in each database, the identified references were exported to the reference manager Mendeley, version X7.</p>
			<p>After selecting the studies, the references were exported to the StArt (State of the Art through Systematic Review) web application for the 2-level selection of studies. The first selection was by reading titles and abstracts, followed by reading the full article. The <italic>Laboratório de Pesquisa em Engenharia de Software</italic> (Software Engineering Research Laboratory, LaPES) of the <italic>Universidade Federal de São Carlos</italic> (UFSCar).</p>
			<p>After data mapping, PRISMA-ScR (extension for scoping reviews) was used for data extraction<sup><xref ref-type="bibr" rid="B20">20</xref></sup>.</p>
		</sec>
		<sec sec-type="results">
			<title>RESULTS</title>
			<p>A total of 264 articles were identified in the databases, of which 115 were duplicates and were excluded, as well as other 127 discarded after reading the titles and abstracts, and nine after reading the full text. Therefore, 13 articles approaching the relation of systemic arterial hypertension as a risk factor for covid-19 aggravation were selected for the study (<xref ref-type="fig" rid="f01">Figure</xref>).</p>
			<p>
				<fig id="f01">
					<label>Figure</label>
					<caption>
						<title>Reference flowchart: inclusion and exclusion of articles. São Carlos, SP, 2021.</title>
					</caption>
					<graphic xlink:href="1518-8787-rsp-56-20-gf01.tif"/>
				</fig>
			</p>
			<p>The 13 publications included (100%) in this scoping review were published in English. Regarding the countries participating in the studies, the following stand out: 10 (76.9%) publications conducted in China, one in Spain (7.7%), one in Germany (7.7%), one in Turkey (7.7%); six of the 13 studies were published in journals from the United States (46.1%), four in English publications (30.8%), one in Switzerland (7.7%), one in China (7.7%), and in one Turkish publication (7.7%). Studies were published from January to December 2020, of which nine (69.2%) were retrospective observational studies and four (30.8%) were cohort studies. After selection, studies were described as to the type of study and objective, and the main results found were extracted, as shown in <xref ref-type="table" rid="t2">Box 2</xref>.</p>
			<p>
				<table-wrap id="t2">
					<label>Box 2</label>
					<caption>
						<title>Description of articles according to author, year, site, objective, type of study, sampling, and main outcomes. São Carlos, SP, 2021.</title>
					</caption>
					<table frame="hsides" rules="groups">
						<colgroup>
							<col/>
							<col/>
							<col/>
							<col/>
						</colgroup>
						<thead>
							<tr>
								<th align="left">Author, Year and Site</th>
								<th>Objective</th>
								<th>Type of study and sampling (n)</th>
								<th>Main results</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td>Chen R, 2020, China<sup>15</sup></td>
								<td align="center">Investigate the association between in-hospital blood pressure control and covid-19-related outcomes, and compare the effects of different antihypertensive treatments.</td>
								<td align="center">Retrospective cohort study. n = 2,828, 51.0% male, and mean age 60.0 years.</td>
								<td align="center">Elevated cardiomyocyte damage biomarkers in grade 2 and grade 3 groups (p &lt; 0.001). Subjects grade 3 group higher B-type natriuretic peptide and worse cardiac function (p &lt; 0.001). Survival rate of adverse clinical outcomes significantly higher in subjects previously treated with renin-angiotensin-aldosterone system inhibitors (HR: 0.35, 95%CI: 0.13–0.97, p = 0.043) or after (HR 0.18, 95%CI: 0.04–0.86, p = 0.031) admission than treated with other antihypertensive medications.</td>
							</tr>
							<tr>
								<td>Rodilla E, 2020, Spain<sup>32</sup></td>
								<td align="center">Analyze whether hypertension represents an independent risk factor for death as a difficult outcome in hospitalized subjects with SARS-CoV-2 in Spain.</td>
								<td align="center">Cross-sectional, observational, multicenter retrospective study. n = 12,226, mean age 67.5, and 42.6% female.</td>
								<td align="center">After adjustment for sex, age tertiles, and Charlson Comorbidity Index scores, hypertension was significantly predictive of all-cause mortality when treated with angiotensin-converting enzyme inhibitors (OR: 1.6, p = 0.002) or other than renin-angiotensin-aldosterone blockers (OR: 1.3, p = 0.001) or angiotensin II receptor blockers (OR: 1.2, p = 0.035).</td>
							</tr>
							<tr>
								<td>Huang S. 2020, China<sup>21</sup></td>
								<td align="center">Explore the effect of hypertension on disease progression and prognosis in subjects with coronavirus 2019 disease (covid-19).</td>
								<td align="center">Multicenter retrospective observational study. n = 310, 56.1% male, and mean age 62 years.</td>
								<td align="center">Comparison hypertensive and non-hypertensive subjects with covid-19 without other comorbidities: hypertension showed no significant correlation with length of stay (p = 0.409) or mortality (p = 0.189) of covid-19 disease, hypertensive subjects higher proportion of severe cases (p &lt; 0.001), higher proportion of intensive care unit admission (p = 0.045). Comparison of laboratory indices between hypertensive subjects with covid-19 with and without other comorbidities, most laboratory indices were not significantly different.</td>
							</tr>
							<tr>
								<td>Okay G, 2020, Turkey<sup>22</sup></td>
								<td align="center">Investigate the effect of hypertension on clinical severity and prognosis of Coronavirus subjects with covid-19.</td>
								<td align="center">Retrospective observational study. n = 260, 55.4% male and mean age 54.1 ± 15.5 years.</td>
								<td align="center">Subjects with severe and critical clinic higher in the hypertensive than in the non-hypertensive group (p &lt; 0.001). Greater use of oxygen therapy in hypertensive than in non-hypertensive subjects (p = 0.001). Higher rate of admission to intensive care unit in hypertensive subjects than in the non-hypertensive group (p = 0.01). Median values of neutrophil count, aspartate aminotransferase, lactate dehydrogenase and creatinine higher in hypertensive subjects than in non-hypertensive subjects. (p = 0.001; p = 0.016; p = 0.002; p &lt; 0.001, respectively). Median albumin values and glomerular filtration rate lower in hypertensive subjects (p = 0.002 and p &lt; 0.001, respectively).</td>
							</tr>
							<tr>
								<td>Ghao G, 2020, China<sup>29</sup></td>
								<td align="center">Investigate whether treatment of hypertension, primarily with renin-angiotensin-aldosterone system (RASA) inhibitors, can impact mortality in subjects with covid-19.</td>
								<td align="center">Retrospective observational study. n = 2,877, hypertensives n = 850 (83.5% taking antihypertensive medications).</td>
								<td align="center">Hypertensive subjects without antihypertensive treatment: higher mortality rate compared to those with antihypertensive treatments (7.9% vs. 3.2%, HR: 2.52, 95%CI: 1.23–5.17, p = 0.012). After adjustment, even higher mortality risk in subjects without antihypertensive treatment (HR: 2.17, 95%CI: 1.03– 4.57,= 0.041). The numerical difference in mortality rates between the renin-angiotensin-aldosterone system inhibitor and non-inhibitor cohorts were not significant before or after adjustment (2.2% vs. 3.6%, adjusted HR: 0.85, 95%CI: 0.28–2.58, p = 0.774).</td>
							</tr>
							<tr>
								<td>Yao Q, 2020, China<sup>24</sup></td>
								<td align="center">Explore the characteristics and differences in outcomes between hypertensive and non-hypertensive subjects with covid-19.</td>
								<td align="center">Observational retrospective study. n = 414, median age 61 years 50.1% male, and 36.0% hypertensive participants.</td>
								<td align="center">Compared with normotensives, hypertensive participants had a higher risk of death (HR: 2.68, 95%CI:1.46– 4.91), after adjustment for age and sex, no difference was shown (HR:1.77, 95%CI: 0.93–3.36). Hypertensive subjects had more complications: shock (p = 0.009), acute respiratory distress syndrome (p = 0.003), acute kidney injury (p = 0.001), greater use of non-invasive mechanical ventilation (p = 0.026), and invasive mechanical ventilation IMV (p = 0.020). Lab results on admission: hypertensive subjects had higher levels of hemoglobin (p = 0.049), D-dimer (p = 0.007), blood urea nitrogen (p = 0.000) and serum creatinine (p = 0.000).</td>
							</tr>
							<tr>
								<td>Xiong TY, 2020, China<sup>25</sup></td>
								<td align="center">Characterize the prevalence and clinical implications of comorbidities in subjects with covid-19.</td>
								<td align="center">Retrospective multicenter study. n = 472 53.0% male, median age 43 years, hypertensive subjects n = 71.</td>
								<td align="center">Comparison hypertensive and non-hypertensive subjects: the hypertensive ones more prone to treatments with angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB), β-blockers, calcium channel blocker (CCB) (p &lt; 0, 001) and statins (p = 0.006), greater chance of experiencing the composite outcome (p &lt; 0.001) and individual outcome, including intensive care unit admission (p &lt; 0.001), mechanical ventilation (p &lt; 0.001) and death (p = 0.012). Occurrence of adverse events did not differ between subjects treated with and without antihypertensive drugs.</td>
							</tr>
							<tr>
								<td>Li J, 2020, China<sup>30</sup></td>
								<td align="center">Investigate the association between angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), and disease severity and mortality in subjects with hypertension hospitalized for covid-19 infection.</td>
								<td align="center">Retrospective study. n = 1,178, hypertensive subjects n = 362 (52.2% male, 71.5% older than 60 years, and 31.8% were on ACEI / ARBs).</td>
								<td align="center">Analysis in the hypertensive group: similar laboratory profile results, except higher alkaline phosphatase in those not taking angiotensin-converting enzyme inhibitors (ACEI) / angiotensin receptor blockers (ARB) (p &lt; 0.001), frequency of disease severity, acute respiratory distress syndrome and mortality did not differ in relation to ACEI / ARB therapy. With regard to IECA/ARB use, there was no difference between those with severe versus non-severe disease in the use of IECA (p = 0.80), ARBs (p = 0.40), or the composite of IECA / ARBs (p = 0.65). Similarly, there were no differences between non-survivors and survivors in the use of IECA (p = 0.85), ARBs (p = 0.42), or the composite of IECA / ARBs (p = 0.34).</td>
							</tr>
							<tr>
								<td>Zhou X, 2020, China<sup>27</sup></td>
								<td align="center">Explore the clinical features of covid-19 complicated by hypertension.</td>
								<td align="center">Single center retrospective study. n = 110, mean age 57.7 years, 54.5% male, hypertensive subjects n = 36 (52.8% male).</td>
								<td align="center">Compared to non-hypertensive subjects, those hypertensive had higher occurrence of dyspnea (p &lt; 0.001), diabetes (p &lt; 0.001) and cardiovascular disease (p = 0.022), lower lymphocyte count on admission (p &lt; 0.01), higher crude mortality rate (p &lt; 0.01). Taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was not significantly associated with prognosis (p = 0.162).</td>
							</tr>
							<tr>
								<td>Chengyi HU, 2020, China<sup>26</sup></td>
								<td align="center">Determine the impact of hypertension on outcomes in subjects with covid-19.</td>
								<td align="center">Observational retrospective cohort study. n = 442, hypertensive subjects n = 61.</td>
								<td align="center">Compared to normotensive subjects, those hypertensive were more likely to develop bacterial infections (p = 0.002), higher neutrophil counts (p = 0.007), neutrophil to lymphocyte ratio (p = 0.045) and lactate dehydrogenase (p = 0.035). A higher proportion of subjects had bilateral irregular opacities on chest CT scan (p = 0.012) in the hypertension group than in the normotensive group. Hypertensive subjects were more likely to receive antibiotics (p = 0.035) and corticosteroid therapy (p = 0.035).</td>
							</tr>
							<tr>
								<td>Pan W, 2020, China<sup>31</sup></td>
								<td align="center">Clarify the impact of hypertension on covid-19, and investigate whether prior use of renin-angiotensin-aldosterone system (RAAS) inhibitors affects the prognosis of covid-19.</td>
								<td align="center">Single center retrospective study. n = 996, hypertensive subjects n = 282.</td>
								<td align="center">Hypertension unpaired cohort (HR 1.80, 95%CI: 1.20–2.70); paired cohort (HR 2.24, 95%CI: 1.36–3.70) independently associated with all causes of mortality in subjects with covid-19. There were no significant differences in baseline clinical characteristics between subjects with hypertension who used and did not use renin-angiotensin-aldosterone system (RASA) inhibitors. All-cause mortality rate was significantly lower in the SRAA inhibitor treatment group than in the no-SRAA inhibitor treatment group (p = 0.037).</td>
							</tr>
							<tr>
								<td>Trump S, 2020, Germany<sup>23</sup></td>
								<td align="center">Evaluate the effect of coexisting cardiovascular disease, in particular hypertension and antihypertensive treatment, on covid-19 pathology and viral clearance.</td>
								<td align="center">Prospective observational cohort study. n = 144, 67.4% male. Hypertensive subjects with or without cardiovascular disease n = 90, and subjects without hypertension and without cardiovascular disease n = 54.</td>
								<td align="center">Higher risk of developing critical covid-19 for hypertensive subjects with/without coexisting cardiovascular disease compared to non-hypertensive subjects (adjusted odds ratio (adjOR) = 4.28, 95%CI: confidence interval: 1.60–11.46, p = 0.028). Patients treated with angiotensin receptor blockers (ARB) increased risk of critical covid-19 compared with non-hypertensive subjects (adjOR = 4.14, 95%CI: 1.01–17.04, p = 0.044). Risk of critical disease lower than for hypertensive subjects without treatment with angiotensin-converting enzyme inhibitors (ACEIs) or ARBs (adjOR = 8.17, 95%CI: 1.65–40.52, p = 0.009). No difference in ACE2 expression and initial viral concentration between subject groups.</td>
							</tr>
							<tr>
								<td>Yang Q, 2020, China<sup>28</sup></td>
								<td align="center">Explore the impact of hypertension on outcomes in subjects with covid-19.</td>
								<td align="center">Retrospective cohort study. n = 226, hypertensive subjects n = 84.</td>
								<td align="center">Subjects divided into survivor and non-survivor groups. Ratio of hypertensive subjects among non-survivors was higher than among survivors (26.70% vs. 74.00%; p &lt; 0.001). Hypertensive subjects had higher risk of death (HR: 2.679, 95%CI: 1.237–5.805; p = 0.012), elevated D-dimer levels (HR: 1.025, 95%CI: 1.011–1.039; p &lt; 0.001) and higher neutrophil to lymphocyte ratio (HR: 1.107, 95%CI: 1.053–1.164; p &lt; 0.001).</td>
							</tr>
						</tbody>
					</table>
				</table-wrap>
			</p>
			<p>Of the 13 studies reviewed, three studies showed that among the subjects who developed the severe form of covid-19, the highest proportion corresponded to the group of hypertensive subjects<sup><xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B21">21</xref></sup>.</p>
			<p>With regard to clinical complications, four studies suggested that hypertensive subjects reported higher rate of admission to the Intensive Care Unit (ICU), with clinical conditions such as shock, acute respiratory distress syndrome and acute kidney injury, in addition to greater use of invasive and non-invasive mechanical ventilation, and were more likely to receive antibiotics and corticosteroid therapy<sup><xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B24">24</xref></sup>.</p>
			<p>The analysis of hypertensive subjects with and without other comorbidities found one study showing that laboratory indexes of both groups were similar<sup><xref ref-type="bibr" rid="B21">21</xref></sup>. On the other hand, five studies found that hypertensive subjects had higher levels of hemoglobin, neutrophils, D-dimer, aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and creatinine when compared to normotensive subjects. The studies, however, also pointed out that hypertensive subjects had lower median values for albumin and glomerular filtration rate<sup><xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B26">26</xref></sup>.</p>
			<p>As for mortality, one study showed that hypertensive subjects had higher risk of death when compared to normotensive subjects; however, after adjusting for age and sex, no difference was observed<sup><xref ref-type="bibr" rid="B24">24</xref></sup>. Two studies indicated that the mortality rate was higher in hypertensive subjects without any antihypertensive treatment, and three studies showed that the use of ACEI/ABB is not significantly associated with prognosis<sup><xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B29">29</xref></sup>. One study showed that after adjustment, hypertension was significantly predictive of all-cause mortality when treated with angiotensin-converting enzyme inhibitors or other than renin-angiotensin-aldosterone blockers or angiotensin II receptor blockers<sup><xref ref-type="bibr" rid="B32">32</xref></sup>.</p>
		</sec>
		<sec sec-type="discussion">
			<title>DISCUSSION</title>
			<p>The studies presented systemic arterial hypertension as the most common chronic disease in subjects diagnosed with covid-19<sup><xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B31">31</xref></sup>. Most studies showed that hypertensive subjects diagnosed with covid-19 had a mean age of more than 60 years<sup><xref ref-type="bibr" rid="B21">21</xref></sup>.</p>
			<p>Due to the high global prevalence of hypertension, this group of people was expected to have a high incidence of covid-19. Added to this condition, age also emerges as one of the risk factors for the development of hypertension, since during the physiological process of aging occur morphological changes, including progressive stiffening and loss of compliance of the major arteries that influence blood pressure levels<sup><xref ref-type="bibr" rid="B3">3</xref></sup>.</p>
			<p>Moreover, studies prior to covid-19 have already addressed the relation of aging as an important risk factor in SARS-CoV-associated disease. One study involving young and old monkeys, both infected with the coronavirus, showed similar levels of viral replication and host response to infection. Old monkeys, however, showed stronger response to infection with increased expression of genes associated with inflammation and, according to the comparative analysis between young and old monkeys, this increase was attributable to aging<sup><xref ref-type="bibr" rid="B33">33</xref></sup>.</p>
			<p>In this scenario, the hypothesis raised would be that the oxidative damage accumulated due to the aging process, added with a weakened antioxidant defense system could cause a disturbance in the balancing redox, which would cause an increase in reactive oxygen species. Thus, oxidative stress may enhance cellular responses of early mediators of inflammation. Besides affecting the innate and adaptive immune system, aging is also associated with a pro-inflammatory state in the host<sup><xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref></sup>.</p>
			<p>In this scoping review, the studies showed that male subjects with systemic arterial hypertension and covid-19 were more likely to progress to severe forms of covid-19, as well as more likely to die than female subjects<sup><xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B30">30</xref></sup>. One hypothesis that could explain these findings is attributed to a potential protection of the X chromosome and sex hormones, which play an important role in the innate and adaptive development of immunity. Since the ACE2 gene is located at the Xp22 locus on the human X chromosome, the presence of alleles would confer resistance to SARS-CoV-2. It is a suggested mechanism to explain the apparent lower female susceptibility to severe covid-19 viral infection<sup><xref ref-type="bibr" rid="B35">35</xref></sup>.</p>
			<p>As for the manifestation of covid-19 symptoms, some studies have shown that subjects with systemic arterial hypertension had more marked cough and dyspnea compared to the non-hypertensive group<sup><xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref></sup>. On the other hand, other studies have indicated that the symptoms did not differ significantly in hypertensive subjects and non-hypertensive subjects<sup><xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B29">29</xref></sup>.</p>
			<p>It is noteworthy that the presence of cough and dyspnea are among the main manifestations observed in the moderate and severe types of covid-19<sup><xref ref-type="bibr" rid="B38">38</xref></sup>. In order to explain the presence or absence of symptoms found in the studies, however, one should consider each individual’s immune response to a viral infection, and analyze the variables that may influence the manifestation of symptoms in hypertensive subjects, such as smoking and history of adjacent respiratory comorbidities.</p>
			<p>As far as drug treatment is concerned, there was no association between the use of any class of antihypertensive and a higher risk of mortality<sup><xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B31">31</xref></sup>. Subjects with systemic arterial hypertension and no antihypertensive treatment had higher mortality rate when compared to hypertensive subjects with antihypertensive treatment<sup><xref ref-type="bibr" rid="B29">29</xref></sup>. However, other studies showed that subjects with and without antihypertensive treatment had similar laboratory profile results, and showed no differences in the occurrence of adverse effects or clinical outcomes<sup><xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B30">30</xref></sup>.</p>
			<p>It is noteworthy that because hypertension is a chronic disease, its control requires treatment with pharmacological and non-pharmacological measures throughout life<sup><xref ref-type="bibr" rid="B3">3</xref></sup>. Therefore, it is essential to investigate adherence to drug therapy, and lifestyle habits of hypertensive individuals.</p>
			<p>Studies prior to the covid-19 pandemic pointed out that the high cost in the purchase of antihypertensive drugs, and the use of combinations of different pharmacological classes were presented as predictive factors for non-adherence to drug therapy, which can lead to deterioration in health<sup><xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref></sup>.</p>
			<p>According to the Pan American Health Organization (PAHO), an estimated 1,130 million people worldwide are diagnosed with systemic arterial hypertension, and less than one in five has it under control. The main factors contributing to the high and growing prevalence of hypertension are unhealthy diets, especially excess sodium, insufficient potassium, physical inactivity, and alcohol consumption<sup><xref ref-type="bibr" rid="B2">2</xref></sup>.</p>
			<p>Therefore, regarding the relation between presence of systemic arterial hypertension diagnosis and its impact on health when associated with SARS-CoV-2 infection, this scoping review showed that hypertensive subjects had more propensity to develop the severe form of covid-19 when compared to non-hypertensive subjects<sup><xref ref-type="bibr" rid="B21">21</xref></sup>. The need for ICU admission as well as the need for non-invasive and invasive ventilation were higher in hypertensive subjects when compared to non-hypertensive subjects<sup><xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B31">31</xref></sup>. As for the mortality rate, a significant increase was observed in the group of hypertensive subjects when compared to normotensive ones<sup><xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref></sup>.</p>
			<p>It is noteworthy that during covid-19 infection, immune cell recruitment may be immune-mediated or in response to direct viral aggression to the endothelium, and may result in generalized endothelial dysfunction associated with apoptosis<sup><xref ref-type="bibr" rid="B41">41</xref></sup>. Hypertensive subjects already present pro-inflammatory state due to endothelial dysfunction related to the pathophysiology of systemic arterial hypertension. Disturbances in the immune system and chronic inflammatory stimulation resulting from hypertension may thus contribute to the progression of severe covid-19.</p>
			<p>In this context, regarding laboratory findings in subjects with covid-19, studies have shown that CD3+ cells, CD4+ cells and CD8+ cells counts were lower in the hypertensive group when compared to normotensive subjects. Plasma levels of interleukin (IL) IL-6 and IL-10, however, were significantly higher in the group of hypertensive subjects with covid-19<sup><xref ref-type="bibr" rid="B31">31</xref></sup>. Among subjects affected by the covid-19, when compared to normotensive subjects, hypertensive subjects had significantly higher counts of D-dimer, neutrophils, neutrophil-lymphocyte ratio, WBC, lactate dehydrogenase (LDH), and creatinine<sup><xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B24">24</xref></sup>.</p>
			<p>In order to explain data found, we highlight studies that have pointed to angiotensin-converting enzyme 2 (ACE2), a peptidase in the renin-angiotensin system (RAS), as the main entry receptor for SARS-CoV-2 in humans. Although endothelial cells in a variety of tissues express little or no ACE2, these cells may be infected by the virus and result in negative regulation. This has impacts on angiotensin II and SARS functions in various tissues, including the vasculature, lung, heart, and kidney<sup><xref ref-type="bibr" rid="B43">43</xref></sup>.</p>
			<p>Due to the pro-inflammatory state of systemic arterial hypertension, excessive activation of coagulation pathways and platelets may still occur, as well as immune cells that will secrete cytokines, antimicrobial peptides and a variety of enzymes, and produce oxygen radicals and other media to exterminate the pathogens. However, excessive activation of these defense cells may cause damage to the respiratory epithelium, increasing the local inflammatory response, and decreasing lung function, thus enabling the covid-19 progression<sup><xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B44">44</xref></sup>.</p>
			<p>The altered parameters are indicative that internal organs with high levels of ACE2 protein expression - such as lung, kidney, and heart - may be more vulnerable to invasion and injury by SARS-CoV-2. Hypertensive subjects tend to develop more severe covid-19, not only through severe inflammatory storms, but also through reduced protection against organ injury due to imbalances in the ACE system. Thus, delay in diagnosis and hospital admission may result in an increased risk of developing the severe form of covid-19 or even lead to death.</p>
			<p>Finally, it should be noted that many chronic diseases, including systemic arterial hypertension, share mechanisms that lead to a pro-inflammatory state, and fading of the immune response. Thus, the body would not be able to effectively control the virus in the initial phase, which would lead to worsening of the disease in subjects with covid-19. However, in addition to the presence of hypertension in individuals with covid-19, other factors should be considered such as aging, adjacent comorbidities, history of drug treatment compliance, and unhealthy lifestyle habits that may influence the control of hypertension and consequently to the worsening of covid-19.</p>
			<p>Finally, it is worth noting that more than 76% of the reviewed publications were from China, as expected; however, studies on the relation of systemic arterial hypertension as a risk factor for covid-19 are currently being conducted and published in different countries.</p>
			<p>Limitations include the fact that only studies in Portuguese, English, and Spanish were included in this review; articles available in full text, and indexing databases were not included in this review.</p>
			<p>Current literature pointed out that systemic arterial hypertension may present a poor prognosis in cases of covid-19 when compared to non-hypertensive subjects. Considering the foregoing, the results of this study reinforce the need for the development of strategies to improve assistance, as well as preventive and educational health actions directed to all hypertensive people, in addition to continuous monitoring of these people affected by covid-19.</p>
		</sec>
		<sec sec-type="conclusions">
			<title>FINAL REMARKS</title>
			<p>Hypertension is one of the main risk factors for adverse outcomes in subjects with covid-19. The results found in this study suggest that hypertension is associated with an increased risk of developing the severe form of covid-19, and increased mortality. However, studies addressing the effects on the outcomes of hypertensive subjects and SARS-CoV-2 infection on prior adherence to antihypertensive medications prior to covid-19 infection are still scarce, as well as studies that review the presence of other preexisting comorbidities in subjects with hypertension affected by covid-19, and how these associated diseases may contribute in the evolution to severe form.</p>
			<p>Studies stratified by sex are needed to clarify the apparent greater susceptibility of males to the evolution of the severe form of SARS-CoV-2 infection. Future studies should include the analysis of individual variables that may influence the outcome of systemic arterial hypertension subjects infected by SARS-CoV-2, such as genetic factors, race/ethnicity, occupation, lifestyle habits, in addition to the evaluation of educational level and diagnosis of the socioeconomic and environmental situation.</p>
		</sec>
	</body>
	<back>
		<ref-list>
			<title>REFERENCES</title>
			<ref id="B1">
				<label>1</label>
				<mixed-citation>1. Pan American Health Organization. World Hypertension Day – 17 May 2021. Washington, DC: PAHO; 2021 [cited 2021 Jun 14]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.paho.org/en/events/world-hypertension-day-17-may-2021">https://www.paho.org/en/events/world-hypertension-day-17-may-2021</ext-link>
				</mixed-citation>
				<element-citation publication-type="webpage">
					<person-group person-group-type="author">
						<collab>Pan American Health Organization</collab>
					</person-group>
					<source>World Hypertension Day – 17 May 2021</source>
					<publisher-loc>Washington, DC</publisher-loc>
					<publisher-name>PAHO</publisher-name>
					<year>2021</year>
					<date-in-citation content-type="cited-date">cited 2021 Jun 14</date-in-citation>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://www.paho.org/en/events/world-hypertension-day-17-may-2021">https://www.paho.org/en/events/world-hypertension-day-17-may-2021</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B2">
				<label>2</label>
				<mixed-citation>2. World Health Organization‎. Improving hypertension control in 3 million people: country experiences of programme development and implementation. Geneva (CH): WHO; 2020 [cited 2021 Jun 14]. Available from: <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/handle/10665/336019">https://apps.who.int/iris/handle/10665/336019</ext-link>
				</mixed-citation>
				<element-citation publication-type="webpage">
					<person-group person-group-type="author">
						<collab>World Health Organization‎</collab>
					</person-group>
					<source>Improving hypertension control in 3 million people: country experiences of programme development and implementation</source>
					<publisher-loc>Geneva (CH)</publisher-loc>
					<publisher-name>WHO</publisher-name>
					<year>2020</year>
					<date-in-citation content-type="cited-date">cited 2021 Jun 14</date-in-citation>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/handle/10665/336019">https://apps.who.int/iris/handle/10665/336019</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B3">
				<label>3</label>
				<mixed-citation>3. Barroso WKS, Rodrigues CIS, Bortolotto LA, Mota-Gomes MA, Brandão AA, Feitosa ADM, et al. Diretrizes Brasileiras de Hipertensão Arterial – 2020. Arq Bras Cardiol. 2021 [cited 2021 Jun 16];116(3):516-658. Available from: <ext-link ext-link-type="uri" xlink:href="http://departamentos.cardiol.br/sbc-dha/profissional/pdf/Diretriz-HAS-2020.pdf">http://departamentos.cardiol.br/sbc-dha/profissional/pdf/Diretriz-HAS-2020.pdf</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Barroso</surname>
							<given-names>WKS</given-names>
						</name>
						<name>
							<surname>Rodrigues</surname>
							<given-names>CIS</given-names>
						</name>
						<name>
							<surname>Bortolotto</surname>
							<given-names>LA</given-names>
						</name>
						<name>
							<surname>Mota-Gomes</surname>
							<given-names>MA</given-names>
						</name>
						<name>
							<surname>Brandão</surname>
							<given-names>AA</given-names>
						</name>
						<name>
							<surname>Feitosa</surname>
							<given-names>ADM</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Diretrizes Brasileiras de Hipertensão Arterial – 2020</article-title>
					<source>Arq Bras Cardiol</source>
					<year>2021</year>
					<date-in-citation content-type="cited-date">cited 2021 Jun 16</date-in-citation>
					<volume>116</volume>
					<issue>3</issue>
					<fpage>516</fpage>
					<lpage>658</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="http://departamentos.cardiol.br/sbc-dha/profissional/pdf/Diretriz-HAS-2020.pdf">http://departamentos.cardiol.br/sbc-dha/profissional/pdf/Diretriz-HAS-2020.pdf</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B4">
				<label>4</label>
				<mixed-citation>4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(20)30183-5">https://doi.org/10.1016/S0140-6736(20)30183-5</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Huang</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Ren</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Zhao</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Hu</surname>
							<given-names>Y</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>
					<source>Lancet</source>
					<year>2020</year>
					<volume>395</volume>
					<issue>10223</issue>
					<fpage>497</fpage>
					<lpage>506</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(20)30183-5">https://doi.org/10.1016/S0140-6736(20)30183-5</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B5">
				<label>5</label>
				<mixed-citation>5. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.2020.1585">https://doi.org/10.1001/jama.2020.1585</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wang</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Hu</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Hu</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Zhu</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>J</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</article-title>
					<source>JAMA</source>
					<year>2020</year>
					<volume>323</volume>
					<issue>11</issue>
					<fpage>1061</fpage>
					<lpage>1069</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.2020.1585">https://doi.org/10.1001/jama.2020.1585</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B6">
				<label>6</label>
				<mixed-citation>6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(20)30566-3">https://doi.org/10.1016/S0140-6736(20)30566-3</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zhou</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Yu</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Du</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Fan</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>Z</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title>
					<source>Lancet</source>
					<year>2020</year>
					<volume>395</volume>
					<issue>10229</issue>
					<fpage>1054</fpage>
					<lpage>1062</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(20)30566-3">https://doi.org/10.1016/S0140-6736(20)30566-3</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B7">
				<label>7</label>
				<mixed-citation>7. Tadic M, Saeed S, Grassi G, Taddei S, Mancia G, Cuspidi C. Hypertension and COVID-19: ongoing controversies. Front Cardiovasc Med. 2021;8:639222. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcvm.2021.639222">https://doi.org/10.3389/fcvm.2021.639222</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Tadic</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Saeed</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Grassi</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Taddei</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Mancia</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Cuspidi</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Hypertension and COVID-19: ongoing controversies</article-title>
					<source>Front Cardiovasc Med</source>
					<year>2021</year>
					<volume>8</volume>
					<size units="pages">639222</size>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcvm.2021.639222">https://doi.org/10.3389/fcvm.2021.639222</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B8">
				<label>8</label>
				<mixed-citation>8. Xia F, Zhang M, Cui B, An W, Chen M, Yang P, et al. COVID-19 patients with hypertension are at potential risk of worsened organ injury. Sci Rep. 2021;11:3779. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41598-021-83295-w">https://doi.org/10.1038/s41598-021-83295-w</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Xia</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Cui</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>An</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>P</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>COVID-19 patients with hypertension are at potential risk of worsened organ injury</article-title>
					<source>Sci Rep</source>
					<year>2021</year>
					<volume>11</volume>
					<size units="pages">3779</size>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41598-021-83295-w">https://doi.org/10.1038/s41598-021-83295-w</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B9">
				<label>9</label>
				<mixed-citation>9. Garcia LB, Centurión OA. Medidas preventivas y manejo diagnóstico y terapéutico de la hipertensión arterial y las crisis hipertensivas. Rev Salud Publica Parag. 2020;10(2):59-66. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18004/rspp.2020.diciembre.59">https://doi.org/10.18004/rspp.2020.diciembre.59</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Garcia</surname>
							<given-names>LB</given-names>
						</name>
						<name>
							<surname>Centurión</surname>
							<given-names>OA</given-names>
						</name>
					</person-group>
					<article-title>Medidas preventivas y manejo diagnóstico y terapéutico de la hipertensión arterial y las crisis hipertensivas</article-title>
					<source>Rev Salud Publica Parag</source>
					<year>2020</year>
					<volume>10</volume>
					<issue>2</issue>
					<fpage>59</fpage>
					<lpage>66</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18004/rspp.2020.diciembre.59">https://doi.org/10.18004/rspp.2020.diciembre.59</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B10">
				<label>10</label>
				<mixed-citation>10. Wei ZY, Qiao R, Chen J, Huang J, Wu H, Wang WJ, et al. The influence of pre-existing hypertension on coronavirus disease 2019 patients. Epidemiol Infect. 2021;149:e4. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1017/S0950268820003118">https://doi.org/10.1017/S0950268820003118</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wei</surname>
							<given-names>ZY</given-names>
						</name>
						<name>
							<surname>Qiao</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Huang</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Wu</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>WJ</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>The influence of pre-existing hypertension on coronavirus disease 2019 patients</article-title>
					<source>Epidemiol Infect</source>
					<year>2021</year>
					<volume>149</volume>
					<elocation-id>e4</elocation-id>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1017/S0950268820003118">https://doi.org/10.1017/S0950268820003118</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B11">
				<label>11</label>
				<mixed-citation>11. Yugar-Toledo JC, Yugar LBT, Tácito LHB, Vilela-Martin JF. Disfunção endotelial e hipertensão arterial. Rev Bras Hipertens. 2015 [cited 2021 Jun 28];22(3):84-92. Available from: <ext-link ext-link-type="uri" xlink:href="https://pesquisa.bvsalud.org/portal/resource/pt/biblio-881232">https://pesquisa.bvsalud.org/portal/resource/pt/biblio-881232</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yugar-Toledo</surname>
							<given-names>JC</given-names>
						</name>
						<name>
							<surname>Yugar</surname>
							<given-names>LBT</given-names>
						</name>
						<name>
							<surname>Tácito</surname>
							<given-names>LHB</given-names>
						</name>
						<name>
							<surname>Vilela-Martin</surname>
							<given-names>JF</given-names>
						</name>
					</person-group>
					<article-title>Disfunção endotelial e hipertensão arterial</article-title>
					<source>Rev Bras Hipertens</source>
					<year>2015</year>
					<date-in-citation content-type="cited-date">cited 2021 Jun 28</date-in-citation>
					<volume>22</volume>
					<issue>3</issue>
					<fpage>84</fpage>
					<lpage>92</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://pesquisa.bvsalud.org/portal/resource/pt/biblio-881232">https://pesquisa.bvsalud.org/portal/resource/pt/biblio-881232</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B12">
				<label>12</label>
				<mixed-citation>12. Nägele MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ. Endothelial dysfunction in COVID-19: current findings and therapeutic implications. Atherosclerosis. 2020;314:58-62. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.atherosclerosis.2020.10.014">https://doi.org/10.1016/j.atherosclerosis.2020.10.014</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Nägele</surname>
							<given-names>MP</given-names>
						</name>
						<name>
							<surname>Haubner</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Tanner</surname>
							<given-names>FC</given-names>
						</name>
						<name>
							<surname>Ruschitzka</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Flammer</surname>
							<given-names>AJ</given-names>
						</name>
					</person-group>
					<article-title>Endothelial dysfunction in COVID-19: current findings and therapeutic implications</article-title>
					<source>Atherosclerosis</source>
					<year>2020</year>
					<volume>314</volume>
					<fpage>58</fpage>
					<lpage>62</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.atherosclerosis.2020.10.014">https://doi.org/10.1016/j.atherosclerosis.2020.10.014</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B13">
				<label>13</label>
				<mixed-citation>13. Du Y, Zhou N, Zha W, Lv Y. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: a meta-analysis. Nutr Metab Cardiovasc Dis. 2021;31(3):745-55. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.numecd.2020.12.009">https://doi.org/10.1016/j.numecd.2020.12.009</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Du</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Zhou</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Zha</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Lv</surname>
							<given-names>Y</given-names>
						</name>
					</person-group>
					<article-title>Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: a meta-analysis</article-title>
					<source>Nutr Metab Cardiovasc Dis</source>
					<year>2021</year>
					<volume>31</volume>
					<issue>3</issue>
					<fpage>745</fpage>
					<lpage>755</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.numecd.2020.12.009">https://doi.org/10.1016/j.numecd.2020.12.009</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B14">
				<label>14</label>
				<mixed-citation>14. Ran J, Song Y, Zhuang Z, Han L, Zhao S, Cao P, et al. Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China. Hypertens Res. 2020;43(11):1267-76. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41440-020-00541-w">https://doi.org/10.1038/s41440-020-00541-w</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ran</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Song</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Zhuang</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Han</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Zhao</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Cao</surname>
							<given-names>P</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China</article-title>
					<source>Hypertens Res</source>
					<year>2020</year>
					<volume>43</volume>
					<issue>11</issue>
					<fpage>1267</fpage>
					<lpage>1276</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41440-020-00541-w">https://doi.org/10.1038/s41440-020-00541-w</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B15">
				<label>15</label>
				<mixed-citation>15. Chen R, Yang J, Gao X, Ding X, Yang Y, Shen Y, et al. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension. J Clin Hypertens. 2020;22(11):1974-83. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/jch.14038">https://doi.org/10.1111/jch.14038</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Chen</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Gao</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Ding</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Shen</surname>
							<given-names>Y</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension</article-title>
					<source>J Clin Hypertens</source>
					<year>2020</year>
					<volume>22</volume>
					<issue>11</issue>
					<fpage>1974</fpage>
					<lpage>1983</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/jch.14038">https://doi.org/10.1111/jch.14038</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B16">
				<label>16</label>
				<mixed-citation>16. Caldeira D, Alves M, Melo RG, António PS, Cunha N, Nunes-Ferreira A, et al. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2020;31:100627. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijcha.2020.100627">https://doi.org/10.1016/j.ijcha.2020.100627</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Caldeira</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Alves</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Melo</surname>
							<given-names>RG</given-names>
						</name>
						<name>
							<surname>António</surname>
							<given-names>PS</given-names>
						</name>
						<name>
							<surname>Cunha</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Nunes-Ferreira</surname>
							<given-names>A</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: systematic review and meta-analysis</article-title>
					<source>Int J Cardiol Heart Vasc</source>
					<year>2020</year>
					<volume>31</volume>
					<size units="pages">100627</size>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijcha.2020.100627">https://doi.org/10.1016/j.ijcha.2020.100627</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B17">
				<label>17</label>
				<mixed-citation>17. Fundação SEADE. Boletim Coronavírus Completo. São Paulo; 2021 [cited 2021 Jul 21]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.seade.gov.br/coronavirus/#">https://www.seade.gov.br/coronavirus/#</ext-link>
				</mixed-citation>
				<element-citation publication-type="webpage">
					<person-group person-group-type="author">
						<collab>Fundação SEADE</collab>
					</person-group>
					<source>Boletim Coronavírus Completo</source>
					<publisher-loc>São Paulo</publisher-loc>
					<year>2021</year>
					<date-in-citation content-type="cited-date">cited 2021 Jul 21</date-in-citation>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://www.seade.gov.br/coronavirus/#">https://www.seade.gov.br/coronavirus/#</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B18">
				<label>18</label>
				<mixed-citation>18. Zhang J, Wu J, Sun X, Xue H, Shao J, Cai W, et al. Association of hypertension with the severity and fatality of SARS-CoV-2 infection: a meta-analysis. Epidemiol Infect. 2020;148:e106. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1017/S095026882000117X">https://doi.org/10.1017/S095026882000117X</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zhang</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Wu</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Sun</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Xue</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Shao</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Cai</surname>
							<given-names>W</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Association of hypertension with the severity and fatality of SARS-CoV-2 infection: a meta-analysis</article-title>
					<source>Epidemiol Infect</source>
					<year>2020</year>
					<volume>148</volume>
					<elocation-id>e106</elocation-id>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1017/S095026882000117X">https://doi.org/10.1017/S095026882000117X</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B19">
				<label>19</label>
				<mixed-citation>19. Aromataris E, Munn Z, editors. JBI manual for evidence synthesis. Adelaide (AU): Joanna Briggs Institute; 2020 [cited 2021 Jun 12]. Available from: <ext-link ext-link-type="uri" xlink:href="https://synthesismanual.jbi.global">https://synthesismanual.jbi.global</ext-link>
				</mixed-citation>
				<element-citation publication-type="webpage">
					<person-group person-group-type="editor">
						<name>
							<surname>Aromataris</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Munn</surname>
							<given-names>Z</given-names>
						</name>
						<role>editors</role>
					</person-group>
					<source>JBI manual for evidence synthesis</source>
					<publisher-loc>Adelaide (AU)</publisher-loc>
					<publisher-name>Joanna Briggs Institute</publisher-name>
					<year>2020</year>
					<date-in-citation content-type="cited-date">cited 2021 Jun 12</date-in-citation>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://synthesismanual.jbi.global">https://synthesismanual.jbi.global</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B20">
				<label>20</label>
				<mixed-citation>20. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467-73. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7326/M18-0850">https://doi.org/10.7326/M18-0850</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Tricco</surname>
							<given-names>AC</given-names>
						</name>
						<name>
							<surname>Lillie</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Zarin</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>O’Brien</surname>
							<given-names>KK</given-names>
						</name>
						<name>
							<surname>Colquhoun</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Levac</surname>
							<given-names>D</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation</article-title>
					<source>Ann Intern Med</source>
					<year>2018</year>
					<volume>169</volume>
					<issue>7</issue>
					<fpage>467</fpage>
					<lpage>473</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7326/M18-0850">https://doi.org/10.7326/M18-0850</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B21">
				<label>21</label>
				<mixed-citation>21. Huang S, Wang J, Liu F, Liu J, Cao G, Yang C, et al. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res. 2020;43:824-31. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41440-020-0485-2">https://doi.org/10.1038/s41440-020-0485-2</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Huang</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Cao</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>C</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study</article-title>
					<source>Hypertens Res</source>
					<year>2020</year>
					<volume>43</volume>
					<fpage>824</fpage>
					<lpage>831</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41440-020-0485-2">https://doi.org/10.1038/s41440-020-0485-2</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B22">
				<label>22</label>
				<mixed-citation>22. Okay G, Durdu B, Akkoyunlu Y, Bölükçü S, Kaçmaz AB, Sümbül B, et al. Evaluation of clinical features and prognosis in COVID-19 patients with hypertension: a single-center retrospective observational study. Bezmialem Sci. 2020;8 Suppl 2:15-21. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.14235/bas.galenos.2020.4978">https://doi.org/10.14235/bas.galenos.2020.4978</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Okay</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Durdu</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Akkoyunlu</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Bölükçü</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Kaçmaz</surname>
							<given-names>AB</given-names>
						</name>
						<name>
							<surname>Sümbül</surname>
							<given-names>B</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Evaluation of clinical features and prognosis in COVID-19 patients with hypertension: a single-center retrospective observational study</article-title>
					<source>Bezmialem Sci</source>
					<year>2020</year>
					<volume>8</volume>
					<supplement>Suppl 2</supplement>
					<fpage>15</fpage>
					<lpage>21</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.14235/bas.galenos.2020.4978">https://doi.org/10.14235/bas.galenos.2020.4978</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B23">
				<label>23</label>
				<mixed-citation>23. Trump S, Lukassen S, Anker MS, Chua RL, Liebig J, Thürmann L, et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nat Biotechnol. 2021;39:705-16. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41587-020-00796-1">https://doi.org/10.1038/s41587-020-00796-1</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Trump</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Lukassen</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Anker</surname>
							<given-names>MS</given-names>
						</name>
						<name>
							<surname>Chua</surname>
							<given-names>RL</given-names>
						</name>
						<name>
							<surname>Liebig</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Thürmann</surname>
							<given-names>L</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19</article-title>
					<source>Nat Biotechnol</source>
					<year>2021</year>
					<volume>39</volume>
					<fpage>705</fpage>
					<lpage>716</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41587-020-00796-1">https://doi.org/10.1038/s41587-020-00796-1</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B24">
				<label>24</label>
				<mixed-citation>24. Yao Q, Ni J, Hu TT, Cai ZL, Zhao JH, Xie QW, et al. Clinical characteristics and outcomes in coronavirus disease 2019 (COVID-19) patients with and without hypertension: a retrospective study. Rev Cardiovasc Med. 2020;21(4):615-25. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.31083/j.rcm.2020.04.113">https://doi.org/10.31083/j.rcm.2020.04.113</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yao</surname>
							<given-names>Q</given-names>
						</name>
						<name>
							<surname>Ni</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Hu</surname>
							<given-names>TT</given-names>
						</name>
						<name>
							<surname>Cai</surname>
							<given-names>ZL</given-names>
						</name>
						<name>
							<surname>Zhao</surname>
							<given-names>JH</given-names>
						</name>
						<name>
							<surname>Xie</surname>
							<given-names>QW</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Clinical characteristics and outcomes in coronavirus disease 2019 (COVID-19) patients with and without hypertension: a retrospective study</article-title>
					<source>Rev Cardiovasc Med</source>
					<year>2020</year>
					<volume>21</volume>
					<issue>4</issue>
					<fpage>615</fpage>
					<lpage>625</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.31083/j.rcm.2020.04.113">https://doi.org/10.31083/j.rcm.2020.04.113</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B25">
				<label>25</label>
				<mixed-citation>25. Xiong TY, Huang FY, Liu Q, Peng Y, Xu YN, Wei JF, et al. Hypertension is a risk factor for adverse outcomes in patients with coronavirus disease 2019: a cohort study. Ann Med. 2020;52(7):361-6. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07853890.2020.1802059">https://doi.org/10.1080/07853890.2020.1802059</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Xiong</surname>
							<given-names>TY</given-names>
						</name>
						<name>
							<surname>Huang</surname>
							<given-names>FY</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>Q</given-names>
						</name>
						<name>
							<surname>Peng</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Xu</surname>
							<given-names>YN</given-names>
						</name>
						<name>
							<surname>Wei</surname>
							<given-names>JF</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Hypertension is a risk factor for adverse outcomes in patients with coronavirus disease 2019: a cohort study</article-title>
					<source>Ann Med</source>
					<year>2020</year>
					<volume>52</volume>
					<issue>7</issue>
					<fpage>361</fpage>
					<lpage>366</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07853890.2020.1802059">https://doi.org/10.1080/07853890.2020.1802059</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B26">
				<label>26</label>
				<mixed-citation>26. Chengyi HU, Lushan X, Hongbo Z, Yanpei Z, Wenfeng Z, Li L, et al. [Effect of hypertension on outcomes of patients with COVID-19]. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40(11):1537-42. Chinese. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.12122/j.issn.1673-4254.2020.11.01">https://doi.org/10.12122/j.issn.1673-4254.2020.11.01</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Chengyi</surname>
							<given-names>HU</given-names>
						</name>
						<name>
							<surname>Lushan</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Hongbo</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Yanpei</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Wenfeng</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>L</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Effect of hypertension on outcomes of patients with COVID-19</article-title>
					<source>Nan Fang Yi Ke Da Xue Xue Bao</source>
					<year>2020</year>
					<volume>40</volume>
					<issue>11</issue>
					<fpage>1537</fpage>
					<lpage>1542</lpage>
					<comment>Chinese</comment>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.12122/j.issn.1673-4254.2020.11.01">https://doi.org/10.12122/j.issn.1673-4254.2020.11.01</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B27">
				<label>27</label>
				<mixed-citation>27. Zhou X, Zhu J, Xu T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors. Clin Exp Hypertens. 2020;42(7):656-60. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/10641963.2020.1764018">https://doi.org/10.1080/10641963.2020.1764018</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zhou</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Zhu</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Xu</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors</article-title>
					<source>Clin Exp Hypertens</source>
					<year>2020</year>
					<volume>42</volume>
					<issue>7</issue>
					<fpage>656</fpage>
					<lpage>660</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/10641963.2020.1764018">https://doi.org/10.1080/10641963.2020.1764018</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B28">
				<label>28</label>
				<mixed-citation>28. Yang Q, Zhou Y, Wang X, Gao S, Xiao Y, Zhang W, et al. Effect of hypertension on outcomes of adult inpatients with COVID-19 in Wuhan, China: a propensity score–matching analysis. Respir Res. 2020;21:172. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12931-020-01435-8">https://doi.org/10.1186/s12931-020-01435-8</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yang</surname>
							<given-names>Q</given-names>
						</name>
						<name>
							<surname>Zhou</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Gao</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Xiao</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>W</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Effect of hypertension on outcomes of adult inpatients with COVID-19 in Wuhan, China: a propensity score–matching analysis</article-title>
					<source>Respir Res</source>
					<year>2020</year>
					<volume>21</volume>
					<size units="pages">172</size>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12931-020-01435-8">https://doi.org/10.1186/s12931-020-01435-8</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B29">
				<label>29</label>
				<mixed-citation>29. Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020;41(22):2058-66. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/eurheartj/ehaa433">https://doi.org/10.1093/eurheartj/ehaa433</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gao</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Cai</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Zhou</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>X</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study</article-title>
					<source>Eur Heart J</source>
					<year>2020</year>
					<volume>41</volume>
					<issue>22</issue>
					<fpage>2058</fpage>
					<lpage>2066</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/eurheartj/ehaa433">https://doi.org/10.1093/eurheartj/ehaa433</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B30">
				<label>30</label>
				<mixed-citation>30. Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020;5(7):825-30. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamacardio.2020.1624">https://doi.org/10.1001/jamacardio.2020.1624</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Li</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Deng</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China</article-title>
					<source>JAMA Cardiol</source>
					<year>2020</year>
					<volume>5</volume>
					<issue>7</issue>
					<fpage>825</fpage>
					<lpage>830</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamacardio.2020.1624">https://doi.org/10.1001/jamacardio.2020.1624</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B31">
				<label>31</label>
				<mixed-citation>31. Pan W, Zhang J, Wang M, Ye J, Xu Y, Shen B, et al. Clinical features of COVID-19 in patients with essential hypertension and the impacts of renin-angiotensin-aldosterone system inhibitors on the prognosis of COVID-19 patients. Hypertension. 2020;76(3):732-41. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/HYPERTENSIONAHA.120.15289">https://doi.org/10.1161/HYPERTENSIONAHA.120.15289</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pan</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Ye</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Xu</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Shen</surname>
							<given-names>B</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Clinical features of COVID-19 in patients with essential hypertension and the impacts of renin-angiotensin-aldosterone system inhibitors on the prognosis of COVID-19 patients</article-title>
					<source>Hypertension</source>
					<year>2020</year>
					<volume>76</volume>
					<issue>3</issue>
					<fpage>732</fpage>
					<lpage>741</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/HYPERTENSIONAHA.120.15289">https://doi.org/10.1161/HYPERTENSIONAHA.120.15289</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B32">
				<label>32</label>
				<mixed-citation>32. Rodilla E, Saura A, Jiménez I, Mendizábal A, Pineda-Cantero A, Lorenzo-Hernández E, et al. Association of hypertension with all-cause mortality among hospitalized patients with COVID-19. J Clin Med. 2020;9(10):3136. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/jcm9103136">https://doi.org/10.3390/jcm9103136</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rodilla</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Saura</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Jiménez</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Mendizábal</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Pineda-Cantero</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Lorenzo-Hernández</surname>
							<given-names>E</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Association of hypertension with all-cause mortality among hospitalized patients with COVID-19</article-title>
					<source>J Clin Med</source>
					<year>2020</year>
					<volume>9</volume>
					<issue>10</issue>
					<size units="pages">3136</size>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/jcm9103136">https://doi.org/10.3390/jcm9103136</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B33">
				<label>33</label>
				<mixed-citation>33. Smits SL, Lang A, Brand JMA, Leijten LM, IJcken WF, Eijkemans MJC, et al. Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog. 2010;6(2):e1000756. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.ppat.1000756">https://doi.org/10.1371/journal.ppat.1000756</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Smits</surname>
							<given-names>SL</given-names>
						</name>
						<name>
							<surname>Lang</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Brand</surname>
							<given-names>JMA</given-names>
						</name>
						<name>
							<surname>Leijten</surname>
							<given-names>LM</given-names>
						</name>
						<name>
							<surname>IJcken</surname>
							<given-names>WF</given-names>
						</name>
						<name>
							<surname>Eijkemans</surname>
							<given-names>MJC</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Exacerbated innate host response to SARS-CoV in aged non-human primates</article-title>
					<source>PLoS Pathog</source>
					<year>2010</year>
					<volume>6</volume>
					<issue>2</issue>
					<elocation-id>e1000756</elocation-id>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.ppat.1000756">https://doi.org/10.1371/journal.ppat.1000756</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B34">
				<label>34</label>
				<mixed-citation>34. Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int. 2009;22(11):1041-50. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1432-2277.2009.00927.x">https://doi.org/10.1111/j.1432-2277.2009.00927.x</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Weiskopf</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Weinberger</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Grubeck-Loebenstein</surname>
							<given-names>B</given-names>
						</name>
					</person-group>
					<article-title>The aging of the immune system</article-title>
					<source>Transpl Int</source>
					<year>2009</year>
					<volume>22</volume>
					<issue>11</issue>
					<fpage>1041</fpage>
					<lpage>1050</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1432-2277.2009.00927.x">https://doi.org/10.1111/j.1432-2277.2009.00927.x</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B35">
				<label>35</label>
				<mixed-citation>35. Devaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multiorgan failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020;53(3):425-35. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jmii.2020.04.015">https://doi.org/10.1016/j.jmii.2020.04.015</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Devaux</surname>
							<given-names>CA</given-names>
						</name>
						<name>
							<surname>Rolain</surname>
							<given-names>JM</given-names>
						</name>
						<name>
							<surname>Raoult</surname>
							<given-names>D</given-names>
						</name>
					</person-group>
					<article-title>ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multiorgan failure, and COVID-19 disease outcome</article-title>
					<source>J Microbiol Immunol Infect</source>
					<year>2020</year>
					<volume>53</volume>
					<issue>3</issue>
					<fpage>425</fpage>
					<lpage>435</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jmii.2020.04.015">https://doi.org/10.1016/j.jmii.2020.04.015</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B36">
				<label>36</label>
				<mixed-citation>36. Bezman NA, Kim CC, Sun JC, Min-Oo G, Hendricks DW, Kamimura Y, et al. Molecular definition of the identity and activation of natural killer cells. Nat Immunol. 2012;13(10):1000-9. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni.2395">https://doi.org/10.1038/ni.2395</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bezman</surname>
							<given-names>NA</given-names>
						</name>
						<name>
							<surname>Kim</surname>
							<given-names>CC</given-names>
						</name>
						<name>
							<surname>Sun</surname>
							<given-names>JC</given-names>
						</name>
						<name>
							<surname>Min-Oo</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Hendricks</surname>
							<given-names>DW</given-names>
						</name>
						<name>
							<surname>Kamimura</surname>
							<given-names>Y</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Molecular definition of the identity and activation of natural killer cells</article-title>
					<source>Nat Immunol</source>
					<year>2012</year>
					<volume>13</volume>
					<issue>10</issue>
					<fpage>1000</fpage>
					<lpage>1009</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni.2395">https://doi.org/10.1038/ni.2395</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B37">
				<label>37</label>
				<mixed-citation>37. Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. Clinic Rev Allerg Immunol. 2019;56(3):308-21. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s12016-017-8648-x">https://doi.org/10.1007/s12016-017-8648-x</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Jaillon</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Berthenet</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Garlanda</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Sexual dimorphism in innate immunity</article-title>
					<source>Clinic Rev Allerg Immunol</source>
					<year>2019</year>
					<volume>56</volume>
					<issue>3</issue>
					<fpage>308</fpage>
					<lpage>321</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s12016-017-8648-x">https://doi.org/10.1007/s12016-017-8648-x</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B38">
				<label>38</label>
				<mixed-citation>38. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Chin Med J (Engl). 2020;133(9):1087-95. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/CM9.0000000000000819">https://doi.org/10.1097/CM9.0000000000000819</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<article-title>Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)</article-title>
					<source>Chin Med J (Engl)</source>
					<year>2020</year>
					<volume>133</volume>
					<issue>9</issue>
					<fpage>1087</fpage>
					<lpage>1095</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/CM9.0000000000000819">https://doi.org/10.1097/CM9.0000000000000819</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B39">
				<label>39</label>
				<mixed-citation>39. Mion Junior D, Silva GV, Ortega KC, Nobre F. A importância da medicação anti-hipertensiva na adesão ao tratamento. Rev Bras Hipertens. 2006 [cited 2021 Jun 27];13(1):55-8. Available from: <ext-link ext-link-type="uri" xlink:href="http://departamentos.cardiol.br/dha/revista/13-1/13-importancia-da-medicacao.pdf">http://departamentos.cardiol.br/dha/revista/13-1/13-importancia-da-medicacao.pdf</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mion</surname>
							<given-names>D</given-names>
							<suffix>Junior</suffix>
						</name>
						<name>
							<surname>Silva</surname>
							<given-names>GV</given-names>
						</name>
						<name>
							<surname>Ortega</surname>
							<given-names>KC</given-names>
						</name>
						<name>
							<surname>Nobre</surname>
							<given-names>F</given-names>
						</name>
					</person-group>
					<article-title>A importância da medicação anti-hipertensiva na adesão ao tratamento</article-title>
					<source>Rev Bras Hipertens</source>
					<year>2006</year>
					<date-in-citation content-type="cited-date">cited 2021 Jun 27</date-in-citation>
					<volume>13</volume>
					<issue>1</issue>
					<fpage>55</fpage>
					<lpage>58</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="http://departamentos.cardiol.br/dha/revista/13-1/13-importancia-da-medicacao.pdf">http://departamentos.cardiol.br/dha/revista/13-1/13-importancia-da-medicacao.pdf</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B40">
				<label>40</label>
				<mixed-citation>40. Santana BS, Rodrigues BS, Stival MM, Volpe CRG. Arterial hypertension in the elderly accompanied in primary care: profile and associated factors. Esc Anna Nery. 2019;23(2):e20180322. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/2177-9465-EAN-2018-0322">https://doi.org/10.1590/2177-9465-EAN-2018-0322</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Santana</surname>
							<given-names>BS</given-names>
						</name>
						<name>
							<surname>Rodrigues</surname>
							<given-names>BS</given-names>
						</name>
						<name>
							<surname>Stival</surname>
							<given-names>MM</given-names>
						</name>
						<name>
							<surname>Volpe</surname>
							<given-names>CRG</given-names>
						</name>
					</person-group>
					<article-title>Arterial hypertension in the elderly accompanied in primary care: profile and associated factors</article-title>
					<source>Esc Anna Nery</source>
					<year>2019</year>
					<volume>23</volume>
					<issue>2</issue>
					<elocation-id>e20180322</elocation-id>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/2177-9465-EAN-2018-0322">https://doi.org/10.1590/2177-9465-EAN-2018-0322</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B41">
				<label>41</label>
				<mixed-citation>41. Brandão SCS, Godoi ETAM, Ramos JOX, Melo LMMP, Sarinho ESC. Severe COVID-19: understanding the role of immunity, endothelium, and coagulation in clinical practice. J Vasc Bras. 2020;19:e20200131. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/1677-5449.200131">https://doi.org/10.1590/1677-5449.200131</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Brandão</surname>
							<given-names>SCS</given-names>
						</name>
						<name>
							<surname>Godoi</surname>
							<given-names>ETAM</given-names>
						</name>
						<name>
							<surname>Ramos</surname>
							<given-names>JOX</given-names>
						</name>
						<name>
							<surname>Melo</surname>
							<given-names>LMMP</given-names>
						</name>
						<name>
							<surname>Sarinho</surname>
							<given-names>ESC</given-names>
						</name>
					</person-group>
					<article-title>Severe COVID-19: understanding the role of immunity, endothelium, and coagulation in clinical practice</article-title>
					<source>J Vasc Bras</source>
					<year>2020</year>
					<volume>19</volume>
					<elocation-id>e20200131</elocation-id>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/1677-5449.200131">https://doi.org/10.1590/1677-5449.200131</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B42">
				<label>42</label>
				<mixed-citation>42. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical &amp; mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-25. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jinf.2020.04.021">https://doi.org/10.1016/j.jinf.2020.04.021</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zheng</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Peng</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Xu</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Zhao</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Peng</surname>
							<given-names>J</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Risk factors of critical &amp; mortal COVID-19 cases: a systematic literature review and meta-analysis</article-title>
					<source>J Infect</source>
					<year>2020</year>
					<volume>81</volume>
					<issue>2</issue>
					<fpage>e16</fpage>
					<lpage>e25</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jinf.2020.04.021">https://doi.org/10.1016/j.jinf.2020.04.021</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B43">
				<label>43</label>
				<mixed-citation>43. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1084/jem.20200652">https://doi.org/10.1084/jem.20200652</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Barnes</surname>
							<given-names>BJ</given-names>
						</name>
						<name>
							<surname>Adrover</surname>
							<given-names>JM</given-names>
						</name>
						<name>
							<surname>Baxter-Stoltzfus</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Borczuk</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Cools-Lartigue</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Crawford</surname>
							<given-names>JM</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Targeting potential drivers of COVID-19: neutrophil extracellular traps</article-title>
					<source>J Exp Med</source>
					<year>2020</year>
					<volume>217</volume>
					<issue>6</issue>
					<elocation-id>e20200652</elocation-id>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1084/jem.20200652">https://doi.org/10.1084/jem.20200652</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B44">
				<label>44</label>
				<mixed-citation>44. Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin Immunopathol. 2016;38(4):471-82. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00281-016-0558-0">https://doi.org/10.1007/s00281-016-0558-0</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Newton</surname>
							<given-names>AH</given-names>
						</name>
						<name>
							<surname>Cardani</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Braciale</surname>
							<given-names>TJ</given-names>
						</name>
					</person-group>
					<article-title>The host immune response in respiratory virus infection: balancing virus clearance and immunopathology</article-title>
					<source>Semin Immunopathol</source>
					<year>2016</year>
					<volume>38</volume>
					<issue>4</issue>
					<fpage>471</fpage>
					<lpage>482</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00281-016-0558-0">https://doi.org/10.1007/s00281-016-0558-0</ext-link>
					</comment>
				</element-citation>
			</ref>
		</ref-list>
		<fn-group>
			<fn fn-type="financial-disclosure" id="fn2">
				<p><bold>Funding:</bold> <italic>Fundação de Amparo à Pesquisa do Estado de São Paulo</italic> (Fapesp - Process 2019/21219-7). Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq - Process 402507/2020-7).</p>
			</fn>
		</fn-group>
	</back>
	<sub-article article-type="translation" id="TRpt" xml:lang="pt">
		<front-stub>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Revisão</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Hipertensão arterial sistêmica como fator de risco para a forma grave da covid-19: revisão de escopo</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-0493-8376</contrib-id>
					<name>
						<surname>Ribeiro</surname>
						<given-names>Ana Cristina</given-names>
					</name>
					<xref ref-type="aff" rid="aff1002"><sup>I</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-0236-5025</contrib-id>
					<name>
						<surname>Uehara</surname>
						<given-names>Sílvia Carla da Silva André</given-names>
					</name>
					<xref ref-type="aff" rid="aff1002"><sup>I</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1002">
				<label>I</label>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal de São Carlos. Departamento de Enfermagem. São Carlos, SP, Brasil</institution>
			</aff>
			<author-notes>
				<corresp id="c01002"> Correspondência: Sílvia Carla da Silva André Uehara Rodovia Washington Luís, s/n, km 235 13565-905 São Carlos, SP, Brasil E-mail: silviacarla@ufscar.br </corresp>
				<fn fn-type="con">
					<p><bold>Contribuição dos Autores:</bold> Concepção e planejamento do estudo: ACR, SCSAU. Coleta, análise e interpretação dos dados: ACR, SCSAU. Elaboração ou revisão do manuscrito: ACR, SCSAU. Aprovação da versão final: ACR, SCSAU. Responsabilidade pública pelo conteúdo do artigo: ACR, SCSAU.</p>
				</fn>
				<fn fn-type="conflict">
					<p><bold>Conflito de Interesses:</bold> Os autores declaram não haver conflito de interesses.</p>
				</fn>
			</author-notes>
			<abstract>
				<title>RESUMO</title>
				<sec>
					<title>OBJETIVO</title>
					<p> Identificar se a hipertensão arterial sistêmica se apresenta como um fator de risco para o agravamento da covid-19.</p>
				</sec>
				<sec>
					<title>MÉTODOS</title>
					<p> Trata-se de uma revisão de escopo, as buscas foram realizadas nas bases de dados Lilacs, PubMed, SciELO e <italic>Web of Science</italic>.</p>
				</sec>
				<sec>
					<title>RESULTADOS</title>
					<p> Foram selecionados 13 artigos. Os estudos apresentaram a hipertensão arterial sistêmica como a doença crônica mais comum em pacientes diagnosticados com covid-19. Os pacientes hipertensos eram mais velhos e os homens se apresentaram mais suscetíveis a desenvolver covid-19 grave. Pacientes hipertensos sem tratamento anti-hipertensivo foram associados a um maior risco de mortalidade.</p>
				</sec>
				<sec>
					<title>CONCLUSÕES</title>
					<p> Pacientes com doenças crônicas tendem a apresentar um perfil clínico diferente, sendo essencial controlar a pressão arterial em pacientes hipertensos e monitorá-los continuamente durante a infecção por covid-19.</p>
				</sec>
			</abstract>
			<kwd-group xml:lang="pt">
				<kwd>COVID-19, complicações</kwd>
				<kwd>Fatores de Risco</kwd>
				<kwd>Hipertensão</kwd>
				<kwd>Revisão</kwd>
			</kwd-group>
		</front-stub>
		<body>
			<sec sec-type="intro">
				<title>INTRODUÇÃO</title>
				<p>A hipertensão arterial sistêmica (HAS) afeta mais de 30% da população adulta, ou seja, mais de um bilhão de pessoas e se apresenta como a principal causa de morte prematura em todo o mundo<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref></sup>. Além disso, a carga da doença é sentida desproporcionalmente em países de baixa e média renda, onde estão dois terços dos casos, em grande parte devido ao aumento de fatores de risco nessas populações nas últimas décadas. Aproximadamente metade das pessoas que vivem com hipertensão arterial desconhecem sua condição, o que as coloca em risco de complicações médicas evitáveis e morte<sup><xref ref-type="bibr" rid="B2">2</xref></sup>.</p>
				<p>Considera-se a hipertensão arterial sistêmica uma doença crônica não transmissível (DCNT), sendo uma condição multifatorial, que depende de fatores genéticos e epigenéticos, ambientais e sociais e seu ponto de corte é definido por pressão arterial sistólica (PAS) ≥ 140 e pressão arterial diastólica (PAD) ≥ 90 mm Hg<sup><xref ref-type="bibr" rid="B3">3</xref></sup>. Dentre os fatores de riscos para o desenvolvimento da HAS, de acordo com as Diretrizes Brasileiras de Hipertensão Arterial – 2020, destacam-se a genética, idade avançada, sexo, etnia, sobrepeso e/ou obesidade, ingestão elevada de sódio, sedentarismo, ingestão de álcool, além de fatores socioeconômicos, incluindo menor escolaridade, condições de habitação inadequadas e baixa renda familiar<sup><xref ref-type="bibr" rid="B3">3</xref></sup>.</p>
				<p>Recentemente, estudos apontaram que a existência de comorbidades, como a hipertensão arterial sistêmica, em pacientes com covid-19 poderiam apresentar desfechos desfavoráveis, incluindo um risco aumentado de morte<sup><xref ref-type="bibr" rid="B4">4</xref></sup>. Nesse cenário, estudos identificaram que a hipertensão é a doença crônica mais comum em pacientes contaminados pelos novo coronavírus, podendo ser justificado pela elevada prevalência global<sup><xref ref-type="bibr" rid="B7">7</xref></sup>.</p>
				<p>Os pacientes com hipertensão arterial sistêmica apresentam disfunção endotelial, que se apresenta como um desequilíbrio entre substâncias vasodilatadoras e vasoconstrictoras que afeta diretamente a função vascular, considerada uma importante característica do leito vascular em hipertensos. Associada ao processo de envelhecimento, a hipertensão resulta no enrijecimento progressivo e na perda de complacência das grandes artérias, sendo crucial na patogênese das complicações cardiovasculares na covid-19<sup><xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref></sup>.</p>
				<p>Ressalta-se que devido ao fato da HAS se apresentar, frequentemente, assintomática, o paciente pode evoluir para alterações estruturais e/ou funcionais em órgãos-alvo, como coração, cérebro, rins e vasos, o que aumentaria a suscetibilidade para o SARS-CoV-2, elevando o risco de desfechos desfavoráveis em pessoas com covid-19<sup><xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B13">13</xref></sup>.</p>
				<p>Os dados sobre o impacto da hipertensão arterial sistêmica conhecida e da diagnosticada recentemente em pacientes com covid-19 ainda são muito limitados. No entanto, um estudo mostrou que o controle insuficiente da pressão arterial (PA) foi independentemente associado a resultados adversos em pacientes com covid-19 e hipertensos<sup><xref ref-type="bibr" rid="B14">14</xref></sup>.</p>
				<p>Nessa mesma linha, um outro estudo relatou que a hipertensão arterial sistêmica em estágio I estava presente em 37% dos pacientes hospitalizados por covid-19, enquanto a prevalência de HAS em estágios II e III era significativamente maior (61% e 70%, respectivamente). Além disso, desfechos desfavoráveis (mortalidade, choque séptico, insuficiência respiratória, síndrome do desconforto respiratório agudo (SDRA) e admissão na unidade de terapia intensiva) aumentaram gradualmente com a elevação da pressão arterial<sup><xref ref-type="bibr" rid="B15">15</xref></sup>.</p>
				<p>Destaca-se ainda que a maioria dos pacientes hipertensos necessita de tratamento farmacológico, principalmente com os inibidores da enzima conversora de angiotensina (IECA) e bloqueadores dos receptores da angiotensina II (BRA) que atualmente tem sido analisado se o uso pode contribuir ou não para um maior risco de infecção e/ou gravidade da covid-19<sup><xref ref-type="bibr" rid="B16">16</xref></sup>.</p>
				<p>A infecção por covid-19 possui letalidade de 2,2% no mundo e atualmente, mais de quatro bilhões de pessoas morreram no mundo, sendo que, somente no Brasil, até julho de 2021, mais de 544 mil pessoas morreram em decorrência do covid-19<sup><xref ref-type="bibr" rid="B17">17</xref></sup>. Quanto à relação entre hipertensão arterial sistêmica e covid-19, pacientes hipertensos com infecção por SARS-CoV-2 apresentaram riscos 2,27 e 3,48 vezes maiores de gravidade e fatalidade, respectivamente, em comparação com os casos de covid-19 sem hipertensão<sup><xref ref-type="bibr" rid="B18">18</xref></sup>.</p>
				<p>Nesse contexto, a relação entre a hipertensão arterial sistêmica e desfechos desfavoráveis da covid-19 são de grande preocupação para a saúde pública, tornando-se essencial a realização de estudos que esclareçam a relação entre o diagnóstico de HAS e o desenvolvimento das formas graves da covid-19. Dessa forma, este artigo tem como objetivo identificar se a HAS se apresenta como um fator de risco para o agravamento da covid-19.</p>
			</sec>
			<sec sec-type="methods">
				<title>MÉTODOS</title>
				<p>Trata-se de uma revisão de escopo, sendo seguidos os seis passos metodológicos descritos pelo Joanna Briggs Institute: (1) identificação da questão de pesquisa; (2) identificação de estudos relevantes; (3) seleção dos estudos; (4) extração de dados; (5) separação, sumarização e relatório de resultados; e (6) divulgação dos resultados<sup><xref ref-type="bibr" rid="B19">19</xref></sup>.</p>
				<p>Para a construção da questão norteadora, aplicou-se a estratégia PCC, que representa uma mnemônica para P (População) (pessoas com diagnóstico de HAS), C (Conceito) (pessoas internadas acometidas pela covid-19) e C (Contexto) (Pandemia covid-19); definida como: Pessoas com diagnóstico de HAS podem apresentar um aumento de risco para caso grave de covid-19?</p>
				<p>A busca dos artigos foi realizada nas bases de dados Lilacs, PubMed, SciELO e <italic>Web of Science</italic>, no período de março a abril de 2021, por dois pesquisadores, individualmente, e as divergências foram discutidas com um terceiro pesquisador e solucionadas por consenso. Foram utilizados como termos de busca: hipertensão, hipertensão arterial, coronavírus, covid-19, Sars-coronavirus e Sars-CoV-2 (<xref ref-type="table" rid="t1002">Quadro 1</xref>).</p>
				<p>
					<table-wrap id="t1002">
						<label>Quadro 1</label>
						<caption>
							<title>Estratégias de busca utilizadas nas bases de dados. São Carlos, SP, 2021.</title>
						</caption>
						<table frame="hsides" rules="groups">
							<colgroup>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left">BASE DE DADOS</th>
									<th>ESTRATÉGIAS DE BUSCA</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td>PubMed</td>
									<td align="center">((hypertension[Title] OR “arterial hypertension”[Title]) AND (((coronavirus[Title] OR “COVID-19”[Title]) OR “SARS-CORONAVIRUS”[Title]) OR “SARS-COV-2”[Title])) NOT pulmonary[Title]</td>
								</tr>
								<tr>
									<td><italic>Web of Science</italic></td>
									<td align="center">TI=(hyperttension OR “arterial hypertension”) NOT TI=(pulmonary) AND TI=( coronavirus OR Covid-19 OR SARS-CORONAVIRUS OR SARS-COV-2)</td>
								</tr>
								<tr>
									<td>Lilacs</td>
									<td align="center">(hypertension OR arterial hypertension [Title words] and coronavirus OR covid-19 OR sars-coronavirus OR Sars-cov-2 [Title words] and not pulmonary [Title words])</td>
								</tr>
								<tr>
									<td>SciELO</td>
									<td align="center">TI=(hypertension OR “arterial hypertension”) NOT TI=(pulmonary) AND TI=(coronavirus OR Covid-19 OR SARS-CORONAVIRUS OR SARS-COV-2)</td>
								</tr>
							</tbody>
						</table>
					</table-wrap>
				</p>
				<p>As buscas foram conduzidas por meio de descritores e seus sinônimos que constam no descritor em ciências da saúde (DeCS) e no <italic>medical subject headings</italic> (MeSH) (<xref ref-type="table" rid="t1002">Quadro 1</xref>).</p>
				<p>Foram incluídos estudos primários publicados em português, inglês e espanhol entre janeiro e dezembro de 2020 e excluídos artigos cujos títulos e resumos não se delimitavam dentro do objetivo da investigação e estudos que abordavam outros fatores de risco, além de artigos de opinião, editoriais e revisões. Também, foram verificadas as listas de referências de todos os estudos encontrados.</p>
				<p>Para a seleção dos estudos, após implementação da estratégia de busca em cada base de dados, as referências identificadas foram exportadas para o gerenciador de referências Mendeley, versão X7.</p>
				<p>Após a seleção dos estudos, as referências foram exportadas para o aplicativo <italic>web StArt (State of the Art through Systematic Review)</italic>, para a seleção dos estudos em dois níveis. A primeira seleção foi realizada por meio da leitura de títulos e resumos, seguida pela leitura do artigo na íntegra. A ferramenta de revisão StArt foi desenvolvida pelo Laboratório de Pesquisa em Engenharia de Software (LaPES) da Universidade Federal de São Carlos (UFSCar).</p>
				<p>Após o mapeamento dos dados, foi utilizado o PRISMA-ScR <italic>(extension for scoping reviews)</italic> para a extração dos dados<sup><xref ref-type="bibr" rid="B20">20</xref></sup>.</p>
			</sec>
			<sec sec-type="results">
				<title>RESULTADOS</title>
				<p>Foram identificados 264 artigos nas bases de dados, dos quais 115 eram duplicatas e foram excluídos, assim como outros 127, descartados após a leitura dos títulos e resumos e nove após a leitura na íntegra. Assim, foram selecionados para o estudo 13 artigos que abordavam a relação da hipertensão arterial sistêmica como fator de risco para agravamento da covid-19 (<xref ref-type="fig" rid="f01002">Figura</xref>).</p>
				<p>
					<fig id="f01002">
						<label>Figura</label>
						<caption>
							<title>Fluxograma de referência: inclusão e exclusão dos artigos. São Carlos, SP, 2021.</title>
						</caption>
						<graphic xlink:href="1518-8787-rsp-56-20-gf01-pt.tif"/>
					</fig>
				</p>
				<p>As 13 publicações incluídas (100%) nesta revisão de escopo foram publicadas em inglês. Em relação aos países participantes dos estudos, destacam-se: 10 (76,9%) publicações realizadas na China, uma na Espanha (7,7%), uma na Alemanha (7,7%), uma na Turquia (7,7%); seis dos 13 estudos foram publicados em periódicos dos Estados Unidos (46,1%), quatro em publicações inglesas (30,8%), uma na Suíça (7,7%), uma na China (7,7%) e em uma publicação turca (7,7%). Os estudos foram publicados entre janeiro e dezembro de 2020, sendo nove (69,2%) estudos observacionais retrospectivos e quatro (30,8%) estudos de coorte. Após a seleção, os estudos foram descritos quanto ao tipo de estudo e objetivo, além de realizar a extração dos principais resultados encontrados, conforme apresentado no <xref ref-type="table" rid="t2002">Quadro 2</xref>.</p>
				<p>
					<table-wrap id="t2002">
						<label>Quadro 2</label>
						<caption>
							<title>Descrição dos artigos, segundo autor, ano, local, objetivo, tipo de estudo, amostra e principais resultados. São Carlos, SP, 2021.</title>
						</caption>
						<table frame="hsides" rules="groups">
							<colgroup>
								<col/>
								<col/>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left">Autor, ano e local</th>
									<th>Objetivo</th>
									<th>Tipo de estudo e amostra (n)</th>
									<th>Principais resultados</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td>Chen R, 2020, China<sup>15</sup></td>
									<td align="center">Investigar a associação entre o controle da pressão arterial intra-hospitalar e os resultados relacionados à covid-19 e comparar os efeitos de diferentes tratamentos anti-hipertensivos.</td>
									<td align="center">Estudo de coorte retrospectivo. n = 2.828, 51,0% sexo masculino e idade média 60,0 anos.</td>
									<td align="center">Biomarcadores de danos aos cardiomiócitos elevados nos grupos de graus 2 e 3 (p &lt; 0,001). Pacientes grupo grau 3 maior peptídeo natriurético do tipo B e pior função cardíaca (p &lt; 0,001). Taxa de sobrevivência de resultados clínicos adversos significativamente maior em pacientes tratados com inibidores do sistema renina-angiotensina-aldosterona antes (HR: 0,35; lC95% 0,13–0,97; p = 0,043) ou depois (HR 0,18; IC95% 0,04–0,86; p = 0,031) da admissão do que tratadas com outros medicamentos anti-hipertensivos.</td>
								</tr>
								<tr>
									<td>Rodilla E, 2020, Espanha<sup>32</sup></td>
									<td align="center">Analisar se a hipertensão representa um fator de risco independente para morte como um desfecho difícil em pacientes hospitalizados com SARS-CoV-2 na Espanha.</td>
									<td align="center">Estudo transversal, observacional, multicêntrico retrospectivo. n = 12.226, idade média 67,5 e 42,6% sexo feminino.</td>
									<td align="center">Após ajuste para sexo, tercis de idade e pontuações do Índice de Comorbidade de Charlson, hipertensão foi significativamente preditiva de mortalidade por todas as causas quando tratada com inibidores da enzima de conversão da angiotensina (OR: 1,6; p = 0,002) ou outros que não bloqueadores renina-angiotensina-aldosterona (OR: 1,3; p = 0,001) ou bloqueadores do receptor de angiotensina II (OR: 1,2; p = 0,035).</td>
								</tr>
								<tr>
									<td>Huang S. 2020, China<sup>21</sup></td>
									<td align="center">Explorar o efeito da hipertensão na progressão da doença e prognóstico em pacientes com doença coronavírus 2019 (covid-19).</td>
									<td align="center">Estudo observacional retrospectivo multicêntrico. n = 310, 56,1% sexo masculino, idade média 62 anos.</td>
									<td align="center">Comparação hipertensos e não hipertensos com covid-19 sem outras comorbidades: hipertensão não mostrou correlação significativa com tempo de internação (p = 0,409) ou mortalidade (p = 0,189) da doença covid-19, pacientes hipertensos proporção maior de casos graves (p &lt; 0,001), proporção maior admissão na unidade de terapia intensiva (p = 0,045). Comparação dos índices laboratoriais entre hipertensos com covid-19 com e sem outras comorbidades, maioria dos índices laboratoriais não eram significativamente diferentes.</td>
								</tr>
								<tr>
									<td>Okay G, 2020, Turquia<sup>22</sup></td>
									<td align="center">Investigar o efeito da hipertensão na gravidade clínica e prognóstico do coronavírus pacientes com covid-19.</td>
									<td align="center">Estudo observacional retrospectivo. n = 260, 55,4% sexo masculino e média de idade 54,1 ± 15,5 anos.</td>
									<td align="center">Pacientes com clínica grave e crítica maior nos hipertensos que no grupo não hipertenso (p &lt; 0,001). Maior uso de terapia de oxigênio em hipertensos do que em não hipertensos (p = 0,001). Taxa de admissão para unidade de terapia intensiva em pacientes hipertensos maior do que no grupo não hipertenso (p = 0,01). Valores medianos de contagem de neutrófilos, aspartato aminotransferase, lactato desidrogenase e a creatinina maior em pacientes hipertensos do que em pacientes não hipertensos. (p = 0,001; p = 0,016; p = 0,002; p &lt; 0,001, respectivamente). Valores medianos de albumina e taxa de filtração glomerular menores em pacientes hipertensos (p = 0,002 e p &lt; 0,001, respectivamente).</td>
								</tr>
								<tr>
									<td>Ghao G, 2020, China<sup>29</sup></td>
									<td align="center">Investigar se o tratamento da hipertensão, principalmente com inibidores do sistema renina-angiotensina-aldosterona (SRAA), pode impactar a mortalidade de pacientes com covid-19.</td>
									<td align="center">Estudo observacional retrospectivo. n = 2.877, hipertensos n = 850 (83,5% em uso de medicamentos anti-hipertensivos).</td>
									<td align="center">Hipertensos sem tratamento anti-hipertensivo: taxa de mortalidade maior em comparação com aqueles com tratamentos anti-hipertensivos (7,9% vs. 3,2%; HR: 2,52; IC95% 1,23–5,17; p = 0,012). Após ajuste, risco de mortalidade ainda maior em pacientes sem tratamento anti-hipertensivo (HR: 2,17; IC95% 1,03–4,57; p = 0,041). A diferença numérica nas taxas de mortalidade entre os coortes de inibidores do sistema renina-angiotensina-aldosterona e não-inibidores não foram significativas antes ou após o ajuste (2,2% vs. 3,6%, HR ajustado: 0,85; IC95% 0,28–2,58; p = 0,774).</td>
								</tr>
								<tr>
									<td>Yao Q, 2020, China<sup>24</sup></td>
									<td align="center">Explorar as características e diferenças de resultados entre pacientes com e sem hipertensão com covid-19.</td>
									<td align="center">Estudo retrospectivo observacional. n = 414, mediana de idade 61 anos 50,1% sexo masculino e 36,0% hipertensos.</td>
									<td align="center">Comparação com normotensos, hipertensos apresentaram maior risco de morte (HR: 2,68; IC95% 1,46–4,91), após ajuste para idade e sexo, nenhuma diferença foi mostrada (HR: 1,77; IC95% 0,93–3,36). Hipertensos tiveram mais complicações: choque (p = 0,009), síndrome do desconforto respiratório agudo (p = 0,003), lesão renal aguda (p = 0,001), maior uso de ventilação mecânica não invasiva (p = 0,026) e ventilação mecânica invasiva VMI (p = 0,020). Resultados laboratoriais na admissão: hipertensos apresentaram maiores níveis de hemoglobina (p = 0,049) D-dímero (p = 0,007), nitrogênio da ureia no sangue (p = 0,000) e creatinina sérica (p = 0,000).</td>
								</tr>
								<tr>
									<td>Xiong TY, 2020, China<sup>25</sup></td>
									<td align="center">Caracterizar a prevalência e as implicações clínicas das comorbidades em pacientes com covid-19.</td>
									<td align="center">Estudo multicêntrico retrospectivo. n = 472 53,0% sexo masculino, mediana de idade 43 anos, hipertensos n = 71.</td>
									<td align="center">Comparação hipertensos e sem hipertensão: hipertensos mais propensos tratamentos com inibidor da enzima de conversão da angiotensina (IECA) / bloqueador do receptor da angiotensina II (ARB), β-bloqueadores, bloqueador dos canais de cálcio (CCB) (p &lt; 0,001) e estatinas (p = 0,006), maior chance de experimentar o desfecho composto (p &lt; 0,001) e desfecho individual, incluindo admissão na unidade de terapia intensiva (p &lt; 0,001), ventilação mecânica (p &lt; 0,001) e óbito (p = 0,012). Ocorrência de eventos adversos não diferiu entre os pacientes tratados com e sem medicamentos anti-hipertensivos.</td>
								</tr>
								<tr>
									<td>Li J, 2020, China<sup>30</sup></td>
									<td align="center">Investigar a associação entre inibidores da enzima de conversão da angiotensina (IECA) e bloqueadores do receptor da angiotensina (BRA) e gravidade da doença e mortalidade em pacientes com hipertensão hospitalizados por infecção por covid-19.</td>
									<td align="center">Estudo retrospectivo. n = 1.178, hipertensos n = 362 (52,2% sexo masculino, 71,5% mais de 60 anos e 31,8% estavam em uso de IECA / BRA).</td>
									<td align="center">Análise no grupo de hipertensos: resultados de perfil laboratorial semelhantes, exceto fosfatase alcalina mais alta naqueles que não tomam inibidores da enzima conversora de angiotensina (IECA) / bloqueadores do receptor da angiotensina (ARB) (p &lt; 0,001), frequência da gravidade da doença, síndrome da angústia respiratória aguda e mortalidade não diferiu em relação à terapia IECA / ARB. Com relação ao uso de IECA / ARB, não houve diferença entre aqueles com doença grave versus não grave no uso de IECA (p = 0,80), ARBs (p = 0,40), ou o composto de IECA / ARBs (p = 0,65). Da mesma forma, não houve diferenças entre não sobreviventes e sobreviventes no uso de IECA (p = 0,85), ARBs (p = 0,42) ou o composto de IECA / ARBs (p = 0,34).</td>
								</tr>
								<tr>
									<td>Zhou X, 2020, China<sup>27</sup></td>
									<td align="center">Explorar as características clínicas do covid-19 complicadas pela hipertensão.</td>
									<td align="center">Estudo retrospectivo de centro único. n = 110, idade média 57,7 anos, 54,5% sexo masculino, hipertensos n = 36 (52,8% sexo masculino).</td>
									<td align="center">Comparados aos não hipertensos, hipertensos apresentaram ocorrência maior de dispneia (p &lt; 0,001), diabetes (p &lt; 0,001) e doença cardiovascular (p = 0,022), menor contagem de linfócitos na admissão (p &lt; 0,01), taxa bruta de mortalidade maior (p &lt; 0,01). Tomar inibidores da enzima conversora de angiotensina ou bloqueadores do receptor da angiotensina não foi significativamente associado ao prognóstico (p = 0,162).</td>
								</tr>
								<tr>
									<td>Chengyi HU, 2020, China<sup>26</sup></td>
									<td align="center">Determinar o impacto da hipertensão nos resultados de pacientes com covid-19.</td>
									<td align="center">Estudo observacional de Coorte retrospectivo. n = 442, hipertensos n = 61.</td>
									<td align="center">Comparação aos normotensos, hipertensos mais propensos a desenvolver infecções bacterianas (p = 0,002), contagens mais altas de neutrófilos (p = 0,007), relação neutrófilos / linfócitos (p = 0,045) e lactato desidrogenase (p = 0,035). Proporção maior de pacientes apresentou opacidades irregulares bilaterais na tomografia computadorizada de tórax (p = 0,012) no grupo de hipertensão do que no grupo de normotenso. Hipertensos mais propensos a receber antibióticos (p = 0,035) e terapias com corticosteroides (p = 0,035).</td>
								</tr>
								<tr>
									<td>Pan W, 2020, China<sup>31</sup></td>
									<td align="center">Esclarecer o impacto da hipertensão na covid-19 e investigar se o uso prévio de inibidores do sistema renina-angiotensina-aldosterona (RAAS) afeta o prognóstico do covid-19.</td>
									<td align="center">Estudo retrospectivo de centro único. n = 996, hipertensos n = 282.</td>
									<td align="center">Hipertensão coorte não pareada (HR 1,80; IC95% 1,20 –2,70); coorte pareada (HR 2,24; IC95% 1,36–3,70) independentemente associada com todas as causas de mortalidade em pacientes com covid-19. Não houve diferenças significativas nas características clínicas básicas entre os pacientes com hipertensão que usaram e não usaram inibidores do sistema renina-angiotensina-aldosterona (SRAA). Taxa de mortalidade por todas as causas foi significativamente menor no grupo de tratamento com inibidores SRAA do que no grupo de tratamento sem inibidor de SRAA (p = 0,037).</td>
								</tr>
								<tr>
									<td>Trump S, 2020, Alemanha<sup>23</sup></td>
									<td align="center">Avaliar o efeito de doenças cardiovasculares coexistentes, em particular de hipertensão e tratamento anti-hipertensivo, na patologia de covid-19 e na depuração viral.</td>
									<td align="center">Estudo de coorte observacional prospectivo. n = 144, 67,4% sexo masculino. Pacientes hipertensos com ou sem doenças cardiovasculares n = 90 e pacientes sem hipertensão e sem doenças cardiovasculares n = 54.</td>
									<td align="center">Maior risco de desenvolver covid-19 crítico para hipertensos com/sem doença cardiovascular coexistente em relação a pacientes não hipertensos (odds ratio ajustada (adjOR) = 4,28, intervalo de confiança de IC95% 1,60–11,46; p = 0,028). Pacientes tratados com bloqueadores do receptor da angiotensina (ARB) risco aumentado de covid-19 crítico em comparação com pacientes não hipertensos (adjOR = 4,14; IC95% 1,01–17,04; p = 0,044). Risco de doença crítica menor do que para pacientes hipertensos sem tratamento com inibidores da enzima conversora de angiotensina (IECA) ou ARB (adjOR = 8,17; IC95% 1,65–40,52; p = 0,009). Sem diferença na expressão de ACE2 e na concentração viral inicial entre os grupos de pacientes.</td>
								</tr>
								<tr>
									<td>Yang Q, 2020, China<sup>28</sup></td>
									<td align="center">Explorar o efeito da hipertensão nos desfechos de pacientes com covid-19.</td>
									<td align="center">Estudo de coorte retrospectivo. n = 226, hipertensos n = 84.</td>
									<td align="center">Participantes divididos em grupos de sobreviventes e não sobreviventes. Proporção de hipertensos entre os não sobreviventes foi maior do que entre os sobreviventes (26,70% vs. 74,00%; p &lt; 0,001). Hipertensos com risco maior de morte (HR: 2,679; IC95% 1,237–5,805; p = 0,012), níveis elevados de dímero D (HR: 1,025; IC95% 1,011–1,039; p &lt; 0,001) e razão de neutrófilos para linfócitos superiores (HR: 1,107; IC95% 1,053–1,164; p &lt; 0,001).</td>
								</tr>
							</tbody>
						</table>
					</table-wrap>
				</p>
				<p>Dos 13 estudos analisados, três estudos mostraram que, dentre os pacientes que desenvolveram a forma grave da covid-19, a maior proporção correspondia ao grupo de hipertensos<sup><xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B21">21</xref></sup>.</p>
				<p>No que se refere às complicações clínicas, quatro estudos indicaram que os hipertensos tinham maior taxa de admissão em unidade de terapia intensiva, apresentando condições clínicas como choque, síndrome do desconforto respiratório agudo e lesão renal aguda, além do maior uso de ventilação mecânica invasiva e não invasiva, além de mais propensos a receber antibióticos e terapias com corticosteroides<sup><xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B24">24</xref></sup>.</p>
				<p>Na análise de hipertensos com e sem outras comorbidades, um estudo evidenciou que os índices laboratoriais de ambos os grupos foram semelhantes<sup><xref ref-type="bibr" rid="B21">21</xref></sup>. Por outro lado, cinco estudos identificaram que pacientes hipertensos apresentaram níveis mais altos de hemoglobina, neutrófilos, D-dímero, aspartato aminotransferase (AST), lactato desidrogenase (LDH) e a creatinina quando comparados com os normotensos. Entretanto, também apontaram que pacientes hipertensos apresentaram valores medianos menores de albumina e taxa de filtração glomerular<sup><xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B26">26</xref></sup>.</p>
				<p>No que se refere à mortalidade, um estudo mostrou que os hipertensos apresentaram maior risco de morte quando comparados com os normotensos; porém, após ajuste para idade e sexo, nenhuma diferença foi observada<sup><xref ref-type="bibr" rid="B24">24</xref></sup>. Dois estudos indicaram que a taxa de mortalidade foi maior em hipertensos sem qualquer tratamento anti-hipertensivo e três estudos evidenciaram que o uso de IECA/BRA não está significativamente associado ao prognóstico<sup><xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B29">29</xref></sup>. Além disso, um estudo mostrou que, após ajuste, a hipertensão foi significativamente preditiva de mortalidade por todas as causas quando tratada com inibidores da enzima de conversão da angiotensina ou outros que não bloqueadores renina-angiotensina-aldosterona ou bloqueadores do receptor de angiotensina II<sup><xref ref-type="bibr" rid="B32">32</xref></sup>.</p>
			</sec>
			<sec sec-type="discussion">
				<title>DISCUSSÃO</title>
				<p>A hipertensão arterial sistêmica foi identificada como a doença crônica mais comum em pacientes diagnosticados com covid-19<sup><xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B31">31</xref></sup>. Além disso, a maioria dos estudos mostrou que os pacientes hipertensos com diagnóstico de covid-19 possuíam média de idade superior a 60 anos<sup><xref ref-type="bibr" rid="B21">21</xref></sup>.</p>
				<p>Devido à elevada prevalência mundial da hipertensão arterial sistêmica, era previsível que esse grupo de pessoas apresentassem uma elevada incidência de covid-19. Agregado a essa condição, a idade também se apresenta como um dos fatores de risco para o desenvolvimento da hipertensão, uma vez que durante o processo fisiológico do envelhecimento, ocorrem alterações morfológicas e incluem o enrijecimento progressivo e perda de complacência das grandes artérias que influenciam nos níveis da pressão arterial<sup><xref ref-type="bibr" rid="B3">3</xref></sup>.</p>
				<p>Ademais, estudos anteriores à covid-19 já abordavam a relação do envelhecimento como um importante fator de risco na doença associada ao SARS-CoV. Destaca-se um estudo envolvendo macacos jovens e idosos, ambos infectados com o coronavírus, em que os níveis de replicação viral e a resposta do hospedeiro à infecção eram semelhantes. Entretanto, os macacos idosos apresentaram uma resposta mais forte à infecção com aumento na expressão de genes associados à inflamação e segundo a análise comparativa entre macacos jovens e idosos, esse aumento era resultado atribuído ao envelhecimento<sup><xref ref-type="bibr" rid="B33">33</xref></sup>.</p>
				<p>Nesse cenário, a hipótese levantada seria de que o dano oxidativo acumulado devido ao processo de envelhecimento e um sistema de defesa antioxidante enfraquecido poderiam causar um distúrbio no equilíbrio redox, o que causaria um aumento de espécies reativas de oxigênio. Assim, o estresse oxidativo pode potencializar as repostas celulares de mediadores precoces da inflamação e além do envelhecimento afetar o sistema imunológico inato e adaptativo, também está associado a um estado pró-inflamatório no hospedeiro<sup><xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref></sup>.</p>
				<p>Nesta revisão de escopo, os estudos apresentaram que pacientes do sexo masculino com hipertensão arterial sistêmica e covid-19, apresentaram maior susceptibilidade para evoluir para as formas graves da covid-19, bem como maior probabilidade de ir a óbito, do que pacientes do sexo feminino<sup><xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B30">30</xref></sup>. Uma hipótese para explicar esses achados se atribui a uma possível proteção do cromossomo X e dos hormônios sexuais, que desempenham um papel importante no desenvolvimento inato e adaptativo da imunidade, uma vez que o gene ACE2 está localizado no locus Xp22 no cromossomo X humano, a presença de alelos conferiria resistência ao SARS-CoV-2, sendo um mecanismo sugerido para explicar a aparente menor susceptibilidade feminina à infecção viral por covid-19 grave<sup><xref ref-type="bibr" rid="B35">35</xref></sup>.</p>
				<p>Quanto à manifestação dos sintomas de covid-19, alguns estudos mostraram que os pacientes com hipertensão arterial sistêmica apresentaram quadros de tosse e dispneia mais acentuados em comparação com o grupo não hipertenso<sup><xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref></sup>. Por outro lado, outros estudos indicaram que os sintomas não diferiram significativamente nos pacientes hipertensos e nos pacientes não hipertensos<sup><xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B29">29</xref></sup>.</p>
				<p>Ressalta-se que a presença de tosse e dispneia estão entre as principais manifestações observadas no tipo moderado e grave da covid-19<sup><xref ref-type="bibr" rid="B38">38</xref></sup>. No entanto, para explicar a presença ou ausência dos sintomas encontrados nos estudos, deve-se considerar a resposta imunológica de cada indivíduo diante de uma infecção viral, além disso, é fundamental a análise de variáveis que possam influenciar quanto a manifestação dos sintomas em hipertensos, como o tabagismo e histórico de comorbidades respiratórias adjacentes.</p>
				<p>No que se refere ao tratamento medicamentoso, o uso de qualquer classe de anti-hipertensivos não foi associado a um maior risco de mortalidade<sup><xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B31">31</xref></sup>. Pacientes com hipertensão arterial sistêmica sem tratamento anti-hipertensivo apresentaram maior taxa de mortalidade quando comparados aos pacientes hipertensos com tratamentos anti-hipertensivos<sup><xref ref-type="bibr" rid="B29">29</xref></sup>. Entretanto, outros estudos apresentaram que pacientes com e sem tratamento anti-hipertensivo tiveram resultados de perfil laboratorial semelhantes e não apresentaram diferenças na ocorrência de efeitos adversos ou nos resultados clínicos<sup><xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B30">30</xref></sup>.</p>
				<p>Destaca-se que pelo fato de a hipertensão arterial sistêmica ser uma doença crônica, seu controle requer tratamento com medidas farmacológicas e não farmacológicas no decorrer de toda a vida<sup><xref ref-type="bibr" rid="B3">3</xref></sup>. Dessa forma, é essencial investigar a adesão à terapia medicamentosa e aos hábitos de vida dos indivíduos hipertensos.</p>
				<p>Estudos anteriores à pandemia de covid-19 apontaram que o custo elevado na compra dos medicamentos anti-hipertensivos e o uso de combinações de classes farmacológicas diferentes se apresentaram como fatores preditivos para a não adesão à terapia medicamentosa, o que pode levar a deterioração na saúde<sup><xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref></sup>.</p>
				<p>Segundo a Organização Pan-Americana da Saúde (OPAS), estima-se que 1.130 milhão de pessoas no mundo possuem diagnóstico de hipertensão arterial sistêmica, e menos de uma em cada cinco a tem sob controle. Os principais fatores que contribuem para a alta e crescente prevalência de hipertensão arterial são as dietas não saudáveis, especialmente o excesso de sódio, potássio insuficiente, inatividade física e consumo de bebidas alcoólicas<sup><xref ref-type="bibr" rid="B2">2</xref></sup>.</p>
				<p>Sendo assim, quanto a relação da presença de diagnóstico de hipertensão arterial sistêmica e o seu impacto sobre a saúde quando associado à infecção pelo SARS-CoV-2, esta revisão de escopo mostrou que os pacientes hipertensos apresentaram uma maior propensão de desenvolver a forma grave da covid-19 quando comparados aos pacientes não hipertensos<sup><xref ref-type="bibr" rid="B21">21</xref></sup>. Além disso, a necessidade de admissão em unidade de terapia intensiva, assim como a necessidade de ventilação não invasiva e invasiva foram maiores nos pacientes hipertensos quando comparados aos pacientes não hipertensos<sup><xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B31">31</xref></sup> e, quanto a taxa de mortalidade, observou-se um aumento significativo no grupo de hipertensos quando comparados aos normotensos<sup><xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref></sup>.</p>
				<p>Destaca-se que durante a infecção pela covid-19, o recrutamento de células imunes pode ser imunomediado ou em resposta pela agressão viral direta ao endotélio, podendo resultar em disfunção endotelial generalizada associada à apoptose<sup><xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B42">42</xref></sup>. Contudo, pacientes hipertensos já apresentam um estado pró-inflamatório decorrente da disfunção endotelial relacionada à fisiopatologia da hipertensão arterial sistêmica. Dessa forma, os distúrbios no sistema imunológico e a estimulação inflamatória crônica resultante da hipertensão podem contribuir para a progressão da covid-19 grave.</p>
				<p>Nesse contexto, no que se refere aos resultados laboratoriais de pacientes com covid-19, estudos mostraram que as contagens de células CD3+, células CD4+ e células CD8+ foram menores no grupo de hipertensos quando comparados aos pacientes normotensos. No entanto, os níveis plasmáticos de interleucina (IL) IL-6 e IL-10 foram significativamente maiores no grupo de hipertensos com covid-19<sup><xref ref-type="bibr" rid="B31">31</xref></sup>. Dentre os pacientes acometidos pela covid-19, quando comparados aos pacientes normotensos, os pacientes hipertensos apresentaram contagens significativamente maiores de dímero D, neutrófilos, proporção de neutrófilos-linfócitos, leucócitos, lactato desidrogenase (LDH) e creatinina<sup><xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B24">24</xref></sup>.</p>
				<p>Desse modo, para explicar os dados encontrados, destaca-se estudos que têm apontado a enzima conversora de angiotensina 2 (ECA2), uma peptidase no sistema renina-angiotensina (SRA), como o principal receptor de entrada para o SARS-CoV-2 em humanos. Embora as células endoteliais em uma variedade de tecidos expressem pouco ou nenhuma ECA2, essas células podem ser infectadas pelo vírus e resultar em uma regulação negativa impactando nas funções da angiotensina II e SRA em vários tecidos, incluindo a vasculatura, pulmão, coração e rim<sup><xref ref-type="bibr" rid="B43">43</xref></sup>.</p>
				<p>Além disso, devido ao estado pró-inflamatório da hipertensão arterial sistêmica, ainda pode ocorrer ativação excessiva de vias de coagulação e plaquetas, assim como de células imunes que irão secretar citocinas, peptídeos antimicrobianos e uma variedade de enzimas, além de produzir radicais de oxigênio e outros mediadores para exterminar os patógenos. Contudo, a ativação excessiva dessas células de defesa pode causar danos ao epitélio respiratório, aumentando a resposta inflamatória local e diminuindo a função pulmonar, proporcionando a progressão da covid-19<sup><xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B44">44</xref></sup>.</p>
				<p>Diante de parâmetros alterados, que se apresentam como indicativos de que órgãos internos com altos níveis de expressão da proteína ECA2, como pulmão, rim e coração podem ser mais vulneráveis à invasão e lesão pelo SARS-CoV-2. Pacientes hipertensos tendem a desenvolver covid-19 mais grave, não apenas por meio de tempestades inflamatórias graves, mas também por meio de proteção reduzida contra lesão de órgão devido a desequilíbrios no sistema ECA. Assim, o atraso no diagnóstico e admissão hospitalar pode resultar em um risco aumentado de desenvolver a forma grave da covid-19 ou até mesmo levar a morte.</p>
				<p>Por fim, é necessário destacar que muitas doenças crônicas, incluindo a hipertensão arterial sistêmica, partilham mecanismos que levam a um estado pró-inflamatório e atenuação da resposta imunológica. Dessa forma, o organismo não poderia controlar efetivamente o vírus na fase inicial, o que levaria ao agravamento da doença em pacientes com covid-19. No entanto, além da presença da hipertensão arterial em indivíduos com covid-19, deve-se levar em consideração outros fatores como o envelhecimento, comorbidades adjacentes, histórico de adesão ao tratamento medicamentoso e hábitos de vida não saudáveis que podem influenciar no controle da hipertensão e consequentemente para o agravamento da covid-19.</p>
				<p>Por fim, vale ressaltar que mais de 76% das publicações revisadas foram oriundas da China, conforme esperado; entretanto, atualmente estudos sobre a relação da hipertensão arterial sistêmica como um fator de risco para o covid-19 estão sendo realizados e publicados em diferentes países.</p>
				<p>Consideram-se como limitações o fato de terem sido incluídos nesta revisão somente estudos em português, inglês e espanhol, artigos que se encontravam disponíveis em texto na íntegra e bases de indexação não incluídos nesta pesquisa.</p>
				<p>A literatura atual tem apontado que a hipertensão arterial sistêmica pode apresentar um mau prognóstico em casos de covid-19 quando comparados aos pacientes não hipertensos. Diante do exposto, os resultados deste estudo reforçam a necessidade de desenvolvimento de estratégias para melhorar a assistência, bem como de ações preventivas e educativas de saúde direcionadas para todas as pessoas hipertensas, além de um monitoramento contínuo com essas pessoas acometidas pela covid-19.</p>
			</sec>
			<sec sec-type="conclusions">
				<title>CONSIDERAÇÕES FINAIS</title>
				<p>A hipertensão arterial sistêmica se apresenta como um dos principais fatores de risco para os resultados adversos de pacientes com covid-19. Os resultados encontrados neste estudo sugerem que a hipertensão arterial está associada a um risco aumentado do desenvolvimento da forma grave da covid-19 e aumento da mortalidade. No entanto, ainda são escassos os estudos que abordem os efeitos nos resultados de pacientes hipertensos e a infecção pelo SARS-CoV-2 quanto à adesão prévia no uso de medicamentos anti-hipertensivos anterior à infecção pela covid-19, bem como analisar a presença de outras comorbidades preexistentes em pacientes com hipertensão acometidos pela covid-19 e como essas doenças associadas podem contribuir na evolução para forma grave.</p>
				<p>Além disso, é necessária a realização de estudos estratificados por sexo para esclarecer a aparente maior suscetibilidade do sexo masculino à evolução da forma grave da infecção pelo SARS-CoV-2.É essencial em estudos futuros a inclusão da análise de variáveis individuais que possam influenciar no desfecho de pacientes com hipertensão arterial sistêmica infectados pelo SARS-CoV-2, como fatores genéticos, raça/etnia, ocupação, hábitos de vida, além da avaliação do grau educacional e diagnóstico da situação socioeconômica e ambiental.</p>
			</sec>
		</body>
		<back>
			<fn-group>
				<fn fn-type="financial-disclosure" id="fn2002">
					<p><bold>Financiamento:</bold> Fundação de Amparo à Pesquisa do Estado de São Paulo (Fapesp - Processo 2019/21219-7). Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq - Processo 402507/2020-7).</p>
				</fn>
			</fn-group>
		</back>
	</sub-article>
</article>